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Introduction
This thesis addresses health-related quality of life (HRQOL) in a heavily 
burdened patient population, namely patients with end-stage renal disease 
(ESRD) in chronic dialysis treatment. For an understanding of the multi-
factorial concept of HRQOL in patients with chronic illness, a wide spectrum 
of research approaches is required. Today, validated self-administered 
questionnaires are the method of choice for assessing HRQOL. 
Simultaneously, a broad collection of demographic and clinical 
characteristics that possibly have impact on patients HRQOL should be 
registered in a clinical trial. By achieving a more comprehensive 
understanding of how ESRD aﬀects HRQOL, and how HRQOL aﬀects clinical 
status and outcome in ESRD patients, health care oﬀered to these patients 
may be improved. 
Deﬁnition and epidemiology of end-stage renal disease 
(ESRD) 
ESRD represents a clinical condition in which there has been an irreversible 
loss of renal function of a degree suﬃcient to render the patient 
permanently dependent of renal replacement therapy (RRT, dialysis or 
transplantation) for survival. This general accepted deﬁnition is an 
operational one, and not deﬁned by a certain level of glomerular ﬁltration 
rate or other objective threshold (1).   ESRD is included in the term chronic 
kidney disease (CKD) stage 5, i.e. glomerular ﬁltration rate (GFR) < 15 ml/
min.  The most common causes of ESRD are hypertension, diabetes, 
glomerulonephritis, interstitial nephritis and polycystic kidney disease. 
Incidence and prevalence of patients in need of RRT are increasing 
worldwide. Increasing prevalence of hypertension and diabetes, as well as 
increased life expectancy in aging populations, contribute to the increase 
(2;3). As a consequence of improved treatment and survival of patients with 
cardiovascular disease during the last decades, more patients with CKD will 
more likely progress to ESRD.  
Mortality rates for ESRD patients in dialysis remain unacceptably high, 
despite technological advances in dialysis treatment and improvements in 
the management of cardiovascular risk factors. Some improvements have 
been reported, as seen in recent data from UK in which 1-year survival 
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during the last decade has improved from 65% to 75% in patients >65 years 
(4). For ESRD patients in Europe and in the United States, 1-year survival 
rates after initiation of dialysis treatment are 81.1 % and 80.4 % respectively 
(5;6).  The corresponding survival rates after ﬁve years are 38.2 % and 35.8 
% (5;6). 
Renal replacement therapy
Chronic renal replacement therapy (RRT) includes either dialysis 
(hemodialysis or peritoneal dialysis) or renal transplantation. 
Hemodialysis (HD)
The majority of patients worldwide on RRT receive HD, more than 1 million 
patients. The patient’s blood is delivered to the dialyzer (“artiﬁcial kidney”) 
through an extracorporeal circuit. The transfer of water, waste products, 
and other solutes occurs through the semi-permeable membrane 
separating the blood from the dialysate. HD usually takes place in 
specialized dialysis units, but is also undertaken in satellite units and at 
home.  HD is usually done for four hours three times weekly. Increased 
frequency of dialysis improves eﬃciency and outcome (7), and this may also 
urge increased use of home hemodialysis.  Patient’s personal preference 
should be taken into consideration when treatment modality for RRT is 
chosen.
Peritoneal dialysis (PD)
PD is used in variable frequencies in diﬀerent countries, but there has been 
an increase in the use of this dialysis modality, currently approximately 
150000 patients worldwide. This is mainly a home-based therapy, and the 
success is based on the patient’s or a caregiver’s ability or competence to 
undertake PD. This necessitates a teaching period in the hospital setting, 
usually in an outpatient clinic.  Both continuous ambulatory peritoneal 
dialysis with manual shift of the dialysate or use of automatic devices taking 
care of the shifts of the dialysate in and out of the abdominal cavity, and 
usually during night-time, are used.  The peritoneal cavity is ﬁlled with ﬂuid 
(dialysate), and the peritoneal membrane serves as endogenous dialyzer.  
Across the peritoneal membrane, waste products, electrolytes and water 
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diﬀuse from the capillaries to the dialysate, a hyper-osmotic ﬂuid, usually 
containing glucose. 
The HD and PD treatment modalities are equal in some aspects, but 
patients are often chosen for PD based on the ability to cope with the 
treatment, cardiovascular instability, and to preserve residual renal 
function. The selection criteria can vary between dialysis centres according 
to clinical traditions.
Renal transplantation (RTX)
RTX is considered the optimal treatment for patients with ESRD due to 
enhanced survival (8), improved HRQOL (9) and lower costs (10).  
Unfortunately, not all patients will receive a renal transplant due to lack of 
donor organs or comorbidity that oﬀset the beneﬁt of RTX. Recipients 
undergo a thorough medical workup and evaluation before they are 
accepted for RTX. The renal graft is provided either from a deceased donor 
or from a living donor.  Living with a functional renal graft frees the patient 
from the exhausting dialysis treatment, yet lifelong immunosuppressive 
medication is mandatory to avoid graft rejection.  Usually patients spend a 
variable duration of time (up to years) awaiting RTX, but pre-emptive RTX 
(before dialysis is needed) are also used in a small proportion of the 
patients. The possibility to get a renal transplant varies greatly between 
countries, even between the Nordic countries.
The Norwegian dialysis population
Currently the number of patients on dialysis treatment is escalating, as an 
increasing number of patients enter into RRT program without possibilities 
for future transplantation.  Figure 1 demonstrates the status of RRT in 
Norway from 1982 to the end of 2009.  As the incidence of patients 
accepted for RRT has increased during the last years in Norway (reaching 
116.3 per million inhabitants by the end of 2009), the number of patients 
receiving chronic dialysis has increased even more.  Number of patients in 
Norway that will be in need of RRT has been estimated to increase 10 % per 
year from 2005 to 2015 according to an expert group in the Norwegian 
Health Directorate (http://www.nephro.no/foreningsnytt/
rapportdialyse2006.pdf), which would result in more than a doubling of the 
Norwegian dialysis population in 10 years. 
11
12
Dialysis modalities 
Data from the Norwegian Renal Registry 2009 expose that approximately 80% of 
the prevalent dialysis patients in Norway receive HD. The use of PD varies widely 
even between renal units in Norway, from 10-30%, and surprisingly more 
frequently used in some urban areas than in rural areas. This is mainly due to 
tradition and experience with PD. More frequent use of home –based therapy is 
encouraged. Small satellite units for HD are established in rural areas in Norway to 
avoid long travel distances. Home hemodialysis is still rarely used in Norway.  
Eligibility for renal transplantation
In Norway, all patients approaching or entering dialysis, are considered for 
renal transplantation. Eligibility for transplantation is based on medical and 
surgical criteria, and not limited by social or economic status. Age and 
gender have not been discriminating factors (12-14). In 2009, 66% of the 
incident dialysis patients were considered potential candidates for 
transplantation, while 34 % were accepted for lifelong dialysis. The most 
common contraindication for renal transplantation has been severe 
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Figure 1. From Annual Report 2009, the Norwegian Renal Registry(11). Courtesy of 
Torbjørn Leivestad
cardiovascular and peripheral artery disease. Severe mental illness and 
dementia may limit access to the waiting list, while malignant diseases 
considered cured pose no absolute contraindication and most patients can 
enter the transplantation programme if they are cancer free after a limited 
period.   
The availability of kidneys is limited, making patients spend months to 
years in dialysis. Not only is the monetary cost tremendous, approximately 
500000-1000000 NOK yearly per patients in hemodialysis (little data 
available on the total cost), including costs of health personnel, travel to 
dialysis 3 or 4 times a week, dialysis treatment and medications. But also 
the individual human burden of entering dialysis treatment is huge. The 
majority of patients lose their workability in the course of the disease, i.e. 
when entering dialysis.
Renal transplantation in Norway
The renal transplantation rate is high in Norway, reaching 60.5 per million 
inhabitants in 2009, where 36% of the transplanted kidneys came from a 
living donor (11).  Thus, the majority of patients on RRT in Norway are 
transplanted, and they constitute more than 2/3 of the RRT population. In 
2009, the median time on the waiting list for RTX was 8 months (range up 
to 74 months) for patients receiving renal graft from a deceased donor. 
Currently the RTX activity is increasing. Because of the high transplantation 
activity, the Norwegian dialysis population is characterized by a rather short 
time in dialysis compared to other countries.  
Deﬁnition of health-related quality of life (HRQOL) 
HRQOL is a multidimensional concept that includes a person’s perception of 
physical functioning, social role functioning, mental health, and general 
health (15).  Three of these domains appear in the World Health 
organization’s deﬁnition of health as a “state of complete physical, mental 
and social well-being and not merely the absence of inﬁrmity and 
diseases” (16).  Because the clinicians are interested in how a particular 
disease and the treatment of the disease aﬀect a patients experience of 
health, the term “health-related quality of life” may be more adequate than 
simply “quality of life”.  Multiple aspects of life exist that are not generally 
considered as "health," including income, freedom, and quality of the 
environment. Nevertheless, these aspects may inﬂuence on a person’s 
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experience of health.  When a patient is ill or diseased, almost all aspects of 
life can become health related (17).  It is important to note that the 
subjective experience of health is inﬂuenced by a person’s beliefs, 
expectations and perceptions(15).
HRQOL measurements are based on a patient’s own (‘‘subjective’’) sense of 
well-being, and the quantitatively HRQOL scores are calculated from self-
reported questionnaires. In patients with chronic illness, HRQOL 
assessments may be used in patient care to screen for and prioritize 
problems, to improve communication between health care workers and 
patients, and to evaluate response to treatment(18). Frequently used HRQOL 
instruments have been validated in numerous studies and long version 
questionnaires have been transformed into short versions (19-21). Simpler 
questionnaires containing even fewer items are warranted. Tailor-made 
instruments containing domains that can be weighted diﬀerently by 
diﬀerent patients, according to which domain they consider most important 
in their lives, has been called for(18).  In this thesis the term HRQOL is used, 
irrespectively of whether generic or disease speciﬁc HRQOL measures are 
described. 
HRQOL in ERSD patients
Figure 2 (modiﬁed after Kalantar-Zadeh & Unruh) demonstrates the 
evolution of views on the optimal treatment of CKD (18). From focusing on 
RRT as a life-saving treatment, and survival the outcome of interest, 
functional status and self-perceived HRQOL has gained increased attention 
from clinicians during the last three decades. The ﬁrst studies addressing 
functional status in ESRD patients used instruments like the Karnofsky 
performance scale (22;23).  When using the Karnofsky performance scale, 
the patients’ level of functioning is evaluated and rated by others (health 
care personal). According to the present standard, by collecting self-
reported HRQOL from validated questionnaires, it is the patients themselves 
that have the “rating role”. As numerous studies have reported strong 
associations between self-reported HRQOL and survival (24-30), we may 
assume that improving HRQOL can improve health and survival further. 
Further research is needed to elaborate this. 
There has been a marked increase in number of publications concerned 
with HRQOL in dialysis patients.  Figure 3 demonstrates number of 
publications registered in www.pubmed.com by using the two search 
connotations “health-related quality of life” and “dialysis” (the search was 
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performed on the 15th of September 2011).  No publications were found up 
to 1970, and 40 in the time period 1st January 1970 to 31st of December 
1979. During the last decade (from 1st of January 2000, until 31st of 
December 2009), a total number of 1972 publications appeared in the Pub 
Med search, demonstrating an exponential rise of attention towards this 
topic. During this period, 2 articles were found that included Norwegian 
renal patients (31;32).
Several studies have reported that HRQOL is substantially impaired in 
dialysis patients compared to general populations (33-38).  Data from the 
large Dialysis Outcomes and Practice Patterns Study (DOPPS) have 
demonstrated that HD patients from the United States, Europe, and Japan 
had much lower PCS and MCS scores than the normative values for their 
respective populations (39). Also when compared to patient populations 
with other chronic illnesses, like diabetes, chronic pulmonary diseases, 
rheumatic diseases and cardiovascular diseases, HRQOL seems especially 
compromised in ESRD patients (40).  While HRQOL has been assessed in 
other patient populations like patients with rheumatic disease(41), there has 
been a paucity of data from Norwegian dialysis patients. Physical factors 
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Figure 2. The evolution of views on the optimal treatment of CKD. 
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such as levels of hemoglobin, albumin, psychosocial factors such as marital 
status, depression, and anxiety levels; together with sociodemographic and 
clinical factors such as age, gender, duration of renal disease and dialysis, 
comorbidity (e.g. diabetes), all seem to have signiﬁcant eﬀects on HRQOL in 
HD and PD patients (42;43).  Further research assessing cross-cultural 
diﬀerences in impact of chronic medical conditions on HRQOL have been 
called for to explain reported variations (44).  In ESRD patients receiving HD, 
diﬀerences in HRQOL scores have been reported between countries. 
Japanese HD-patients reported better physical functioning than HD-
patients in the United States or Europe, but they also reported the highest 
burden of kidney disease (39). Due to cultural diﬀerences, it is of high 
importance to assess HRQOL in a representative population of Norwegian 
dialysis patients. 
Research regarding HRQOL in HD and PD patients has yielded somewhat 
conﬂicting results. A meta-analysis performed by Cameron et al (45) 
showed that ambulatory PD patients perceived greater well-being than in-
centre HD patients; the latter were associated with greater distress (45). 
Because patients are not randomly assigned to HD and PD treatments, 
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Figure 3. From a Pub Med search on the terms “health-related quality of life” and 
“dialysis”, number of publications (abscissa) by time (ordinate) are shown. The search 
took place in September 2011. Decades (i.e. 1st of January 1970 until 31st of December 
1979) are shown; in addition number of publications from the year 2010 is shown in the 
column to the utter right.
treatment groups frequently diﬀer with respect to many characteristics that 
may be associated with HRQOL, such as age and comorbid illnesses. Data 
from the Northern Thames study (46) indicates that PD in elderly dialysis 
patients is associated with better disease speciﬁc HRQOL than HD.  Due to 
lack of previous Norwegian data it was important to assess HRQOL in a 
representative sample of both HD and PD patients.  
Renal transplantation is expected to improve HRQOL in dialysis patients 
(47;48). However, there is a paucity of data reporting whether acceptance 
status for renal transplantation aﬀects HRQOL in dialysis patients. Figure 4 
demonstrates the process of referral and planning of renal transplantation 
in CKD patients (49).  Initiation of pre-transplant investigations may start at 
diﬀerent moments during the course of CKD. Thus, patient with CKD may 
be accepted for RTX before the onset of dialysis (with possibility for pre-
emptively transplantation), or after dialysis initiation (Figure 4). This means, 
that when assessing HRQOL in prevalent dialysis patients, patients will diﬀer 
in regard to their prospect of being transplanted or not.   Dialysis patients 
have been suggested to cope better with dialysis if treatment is temporary 
and preceding RTX, rather than permanent and deprived of any prospect of 
RTX (50).  Comparative studies, though small, have shown lower depression 
scores in kidney transplant patients compared to dialysis patients (51-53), 
a result conﬁrmed in a longitudinal study of 88 dialysis patients who 
underwent RTX (54).  To the best of our knowledge, no studies have 
explored whether dialysis patients waiting for RTX have better HRQOL and 
less depression compared to those who have been rejected for RTX.  In a 
recent study Kuntz et al examined prevalence of psychiatric distress by 
using the Patient Health Questionnaire in a sample of 518 ESRD patients at 
the speciﬁc time point immediately upon initial referral to a transplant 
center(55).  The prevalence of depression was lower than expected (15.1 %), 
but the authors point to the lack of clarity in the literature about renal 
patients’ self-report of psychological distress during the critical moments 
of initial consideration for transplant(55).   It is important to achieve a 
better understanding of how acceptance status for RTX aﬀects HRQOL in 
dialysis patients. Especially because some patients are rejected for this 
treatment, and an increasing number of patients are recruited into life-long 
dialysis.   
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Improved HRQOL has become a well acknowledged treatment goal in 
patients with ESRD (50).  HRQOL is both an important outcome of health 
care and a major determinant of outcome because a close relationship 
exists between QOL, morbidity and mortality (24;25). The importance of 
identifying modiﬁable factors that aﬀects HRQOL in this burdened patient 
population cannot be overemphasized.  Despite this knowledge, there was a 
paucity of data regarding HRQOL in the Norwegian dialysis population until 
recently. Figure 5 gives an overview of the aspects addressed in the cross-
sectional part of the present study, which will be discussed in the thesis 
(paper I-III).  Furthermore, the impact of HRQOL on mortality (paper III), and 
the eﬀect HRQOL or depression on the likelihood of receiving a renal 
transplant (paper II) are reported based on longitudinal data. 
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Figure 4. The process of planning for RRT for patients in the NEPHROLOR network. 
Evaluation of a potential transplant recipient could start at three diﬀerent moments during 
the course of chronic kidney disease: very early referral to a nephrologist with acceptance 
for renal transplantation before starting dialysis and possible pre-emptive transplantation 
(arrow 1), concurrent evaluation for planned dialysis and acceptance to renal 
transplantation (arrow 2) and late referral with dialysis start in an emergency setting and 
pre-transplant evaluation starting after onset of dialysis. Bayat S et al. Nephrol Dial 
Transplant 2006 ;21: 2900-7.  The Figure is adapted with kind permission from the 
authors (49).
Tools to measure HRQOL in ESRD patients
To assess HRQOL, validated self-administered questionnaires are applied.  
A combined approach, using generic measurement augmented by disease-
speciﬁc measurement is the recommended strategy (17;19). The Medical 
Outcome Study 36-item Short Form Health Survey (SF-36)(56) is a patient 
self-reported measure of HRQOL that has been used and validated among 
the general population and among various disease populations, including 
patients with kidney disease. The SF-36 captures the multidimensional 
nature of HRQOL, measuring 8 domains of functioning and also yielding 
component summary scores for the 2 primary dimensions of functioning: 
physical (PCS) and mental (MCS). The SF-12 (57), a shortened version of the 
SF-36 questionnaire was originally designed to reproduce component 
summary scores based  on fewer items than the  SF-36. The SF-12 contains 
a subset of 12 items from the SF-36, including one or two items from each 
of the eight SF-36 subscales (57). In the U.S. general population, the SF-12 
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Figure 5.  Diﬀerent aspects that may have impact on HRQOL in ESRD patients: markers of 
present clinical condition, acceptance status for renal transplantation, presence of clinical 
signiﬁcant depression and level of depressive symptoms, as well as sociodemographic 
factors are all assessed in the thesis (paper I-III).
20
summary scores (PCS-12 and MCS-12) based on the 12 items, explained 
more than 90% of the variance in the SF-36 physical (PCS-36) and mental 
(MCS-36) component summary scores (57).  Yet, the SF-12 has been rarely 
used for patients on dialysis, despite the advantage that it comprises only 
one third of the items compared to SF-36 (58). Speciﬁc kidney disease 
related quality of life was assessed in the present study by using the 
KDQOL-SF version 1.3 (59).  
Depression in ESRD
Depression is reported to be the most common psychological problem 
presented by patients maintained on dialysis therapy (60;61). Depression is 
associated with poorer clinical outcomes and depression is potentially 
treatable in dialysis patients. Thus, it is important for dialysis units to 
develop strategies for screening, assessing and treating dialysis patients for 
clinical signiﬁcant symptoms of depression (62). Relatively recent 
epidemiological evidence suggest that the rate of psychiatric disorders in 
the ESRD population is substantially higher than that observed in other 
chronic medical conditions (63). Estimates of the prevalence of depression 
in ESRD patients are particularly high, suggesting that 12-40% meet 
diagnostic criteria for a mood disorder(64).
 
Researchers in the ﬁeld of renal disease have often not distinguished 
between the diagnosis of major depression and high levels of depressive 
aﬀects. Assessment of depressive aﬀects has often been conducted with 
Beck Depression Inventory (BDI)(65). This inventory assesses both somatic 
and psychological aspects of depression. Neurovegetative symptoms of 
depression, including fatigue, cognitive deﬁcits, decreased appetite, 
insomnia, and loss of libido, may occur secondary to chronic renal failure 
and in the absence of a depressive syndrome. Additionally, conditions 
associated with ESRD such as anemia, diabetes, and electrolyte 
disturbances, may mimic depressive symptoms (66). The assessment and 
diagnosis of depression in ESRD patients, is complex because of the 
potential symptom overlap between the two conditions.  Neither the level of 
depressive symptoms nor the prevalence of clinical signiﬁcant symptoms of 
depression had previously been assessed in Norwegian dialysis patients. It 
was therefore of high importance to explore this in a representative sample 
of Norwegian dialysis patients. 
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Smoking and depression
Epidemiological data have demonstrated a strong association between 
smoking and depression (67-70). Little is known about this association in 
dialysis patients. Few studies have addressed this relationship in ESRD 
patients, but in a recent Danish study from 2007, smoking was found to be 
associated with worse scores on a number of HRQOL scales in 130 dialysis 
patients (71).  Smoking has also been highlighted as an independent 
predictor of poor HRQOL in a longitudinal study of adults with diabetes 
(type 1 diabetes: n=490, and type 2 diabetes: n=1147) published in 2011 
(72). Increased focus on lifestyle factors, including smoking, was pointed 
out in order to improve HRQOL in these patients.  Smoking is a well-known 
risk factor for cardiovascular disease in ESRD patients(73). Yet, little is still 
known about the relationship of smoking with HRQOL in ESRD patients. As 
smoking is a potential modiﬁable factor, it is necessary to gain more 
knowledge about how smoking associates with HRQOL and depression in 
ESRD patients. 
 
Hypothesis
Given this background, we hypothesized that 
•    HRQOL would be compromised in Norwegian dialysis patients 
compared with the general Norwegian population, and clinical signiﬁcant 
symptoms of depression would be prevalent (paper I).
•     Smoking would be associated with reduced HRQOL and increased 
level of depressive symptoms in dialysis patients (paper I).
•     Patients who are not accepted (rejected) for RTX and facing life-long 
dialysis treatment experience reduced HRQOL and higher levels of 
depressive symptoms than patients accepted for RTX (paper II). 
•     Component summary scores from SF-12 and SF-36 are highly 
correlated in dialysis patients (paper III). 
•     Self-assessed HRQOL based on the SF-12 and the SF-36 component 
summary scores would provide similar predictions of mortality in patients 
on dialysis (paper III).
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Aims of the study
•          To explore both HRQOL and prevalence of clinical signiﬁcant 
symptoms of depression in Norwegian chronic dialysis patients (paper I). 
• To study possible associations between HRQOL, depression and 
current smoking status in dialysis patients (paper I).
• To compare HRQOL and depression in dialysis patient accepted or 
rejected for RTX (paper II). 
• To investigate whether HRQOL or depression predict the likelihood of 
RTX  in patients still awaiting a decision on RTX acceptance (paper II). 
• To assess HRQOL with SF-12 and SF-36 component summary scores, 
and compare their abilities to predict mortality in chronic dialysis patients, 
after adjusting for traditional risk factors (paper III). 
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2Material and methods
Study design
A cross-sectional design was chosen for the explorative part of the study.  
As the catchment area exceeded 1 million inhabitants, the study is 
considered population based. Information of HRQOL, depression, clinical 
and sociodemographic data were collected cross-sectionally. HRQOL 
impairments and prevalence of depression could be estimated based on the 
cross-sectional data. The study patients were followed for 3-4 years.  Time 
of death, cause of death and time of renal transplantation were registered in 
the prospective longitudinal study. Thus, the eﬀect of HRQOL on mortality 
and on the likelihood of renal transplantation could be assessed. 
Patients and recruitment procedure
Prevalent dialysis patients from 10 diﬀerent hospitals (ﬁve university 
hospitals and ﬁve regional hospitals) from diﬀerent parts of Norway (Health 
Regions North, West, and South-East) participated in the study. The study 
centers provide renal health care for more than two million Norwegian 
inhabitants, close to half of the total Norwegian population. Two of the 
centers supply health care mainly for an urban population, whereas the 
other hospitals receive patients from both rural and urban areas. The 
following centers participated in the present study: Akershus University 
Hospital, Østfold Regional Hospital, Vestfold Regional Hospital, Buskerud 
Regional Hospital, Elverum Hospital, Lillehammer Hospital, Stavanger 
University Hospital, Haukeland University Hospital, Tromsø University 
Hospital, and Oslo University Hospital Ullevål. 
Inclusion criteria:
• Age ≥ 18 years
• Maintenance dialysis (HD or PD) for 2 months or more
• Clinically stable condition during the last 4 weeks 
• Adequate oral and written Norwegian language skills 
• Signed, informed consent 
Exclusion criteria:
• Cognitive dysfunction (dementia or mental retardation)
• Psychosis or drug abuse
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• Hospitalization during the investigation period excluded patients from the 
study; however, they could be enrolled four weeks or more after discharge 
from hospital if they were clinically stable.
Recruitment procedure
Dialysis patients were enrolled in the study consecutively from August 2005 
to February 2007. A total of 530 dialysis patients at the study centers were 
evaluated for study participation (see ﬂowchart, Figure 6). Of the 416 
patients considered eligible for the study, 326 patients consented to study 
participation, and 301 could be enrolled (enrollment rate of 72.4%, Figure 
6).  The data from the cross-sectional study could be linked with data on 
mortality and transplantation in the Norwegian Renal Registry (NRR). In 
January 2010, data on time of death, cause of death and time of renal 
transplantation were collected from the NNR, and coupled with the cross-
sectional data. The median follow-up time for the prospective part of the 
study was 3.6 years, and none of the patients were lost from follow-up.
Before starting the data collection, informative lectures about the study 
were held for the staﬀ at all study centers. Afterwards, especially dedicated 
study personnel (one or two nurses from each center, usually one working 
with HD and one working with PD), attended a seminar held at Oslo 
University Hospital Ullevål to learn about the aims and methodology of the 
study. This was done in order to enhance standardized use of the 
instruments.
After the patients consented to study participation, they were included in 
the study. Clinical and sociodemographic data were collected. Hemodialysis 
patients answered the self-administered questionnaires during the dialysis 
treatment. A trained study doctor or study nurse gave instructions in how to 
answer the questionnaire to the patients at time of study inclusion, and was 
available for assistance if needed.   If assistance was necessary, the patients 
were dialyzed in a separate room to secure discretion. None of the HD 
patients in this study received the questionnaire by post.  Most patients 
completed the questionnaire during one dialysis session. PD patients were 
informed about the questionnaires in a similar way during a regular visit at 
the outpatient clinic.  Most of them were able to answer the questionnaire 
during their stay in the outpatient clinic at a regular visit.  Some of the PD 
patients brought the questionnaire with them home, if spending time in 
hospital was not feasible. All questionnaires were returned. 
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2Demographic and clinical data collection 
Data collected for the cross-sectional study (Paper I) were used as baseline 
data in the prospective studies (Paper II and Paper III).
Demographic data
The study doctor or nurse completed the Clinical report form, containing 
both demographic and clinical data, before the patient answered the 
questionnaires. Demographic data included age, gender, marital status, 
education, work status and information on smoking habits. The clinical and 
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Figure 6. Flowchart of the recruitment process (paper I, (74))
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laboratory data were collected from reviews of hospital charts. Demographic 
data were attained by reviews of hospital charts and questionnaires, in 
addition to direct questioning the patients. 
Data on smoking habits
Information about current smoking status (yes/no) and number of daily 
smoked cigarettes was collected by direct verbal questioning the patients 
(“do you smoke?” and “how many cigarettes do you smoke a day?), at the 
time of study inclusion. Additionally, cross-checking with available 
information in the hospital’s charts was done.  The credibility of this 
information was considered high, due to the frequent communication 
between patients and health personal, and the time spent in the hospital. 
Data on previous smoking habits and number of daily smoked cigarettes 
were gathered in self-administered questionnaire at the time of the study. 
Clinical data
Cause of renal failure, dialysis modality, dialysis vintage, comorbidities, 
history of previous renal transplantation, present acceptance for renal 
transplantation status, and clinical and laboratory data were collected from 
the hospital charts. Laboratory data like hemoglobin, albumin, C-reactive 
protein, total cholesterol were obtained from the monthly routine blood 
sampling, the last one taken before study participation. Predialysis blood 
pressure was registered at three separate dialysis session, the session at 
the study inclusion day and the two preceding adjacent sessions.  An 
average of the three measurements could be estimated. Body mass index 
was calculated from height and bodyweight (weight was measured 
predialysis for HD patients, and for PD patients without dialysate ﬂuid in the 
peritoneal cavity).
Data on acceptance status for renal transplantation
Acceptance status for renal transplantation was categorized as accepted (on 
waiting list for deceased kidney transplant, or accepted for living donor 
transplantation), pending status i.e. considered as a potential candidate for 
transplantation but awaiting a decision, or rejected. 
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2The Charlson Comorbidity Index
Comorbidity was measured using the modiﬁed Charlson Comorbidity Index 
(CCI). The CCI has been validated for dialysis patients and found to be a 
strong predictor of clinical outcomes (75). The CCI is a composite score of 
17 comorbid conditions and age. Comorbid conditions are given scores 
ranging from 1 to 6, and a score of 1 was added for each decade over 40 
years of age. In this study, CCI was also calculated without including age to 
evaluate the eﬀect of age as a separate factor in multivariate analysis. 
Figure 7 summarizes the comorbid conditions included in the CCI, and their 
scores.
Questionnaires
The Kidney Disease and Quality of Life Short Form, version 1.3, (KDQOL-SF) 
(59) was applied to assess HRQOL.  The Medical Outcome Study 36-item 
Short Form Health Survey (SF-36) (56) was administered as the ﬁrst part of 
the KDQOL-SF, to measure generic dimensions of HRQOL.
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Comorbidity score Conditions (n=17)
1 Coronary artery disease
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Connective tissue disorder
Peptic ulcer disease
Mild liver disease
Diabetes
2 Hemiplegia
Severe renal disease
Diabetes with end-organ damage
Any tumours, leukaemia, lymphoma
3 Moderate or severe liver disease
6 Metastatic solid tumour
AIDS
Figure 7.  Charlsons Comorbidity Index
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SF-36
It consists of 36 items, 35 of which form eight multi-item scales: physical 
function, role limitation because of physical problems, bodily pain, general 
health perception, vitality, social functioning, role limitation because of 
emotional problems and mental health. Two component summary scores 
are derived from the eight subscales: the physical component summary 
scale (PCS) and the mental component summary scale (MCS). A Norwegian 
version of the SF-36 has been validated (76), and population norms 
established (77). 
SF-12
The embedded SF-12(57) comprises 12 questions from the SF-36, and the 
component summary scores of SF-12 were calculated with the algorithm 
from the KDQOL working group (http://gim.med.ucla.edu/kdqol/
downloads).
KDQOL-SF 1.3
The KDQOL questionnaire was developed by the Rand group in 1990 (59) to 
address kidney disease-speciﬁc HRQOL. Forty-three items are classiﬁed 
into 11 speciﬁc kidney-related scales: symptoms, eﬀect of kidney disease, 
burden of kidney disease, work status, cognitive function, quality of social 
interactions, sexual function, sleep, social support, dialysis staﬀ 
encouragement and patient satisfaction. The KDQOL-SF has been applied in 
several international studies on dialysis patients(42), and in a Scandinavian 
population (78). The questionnaire was translated into Norwegian and 
back-translated to American English, as instructed by the Rand group. 
Rigorous back-translation and pre-testing of the kidney speciﬁc scales were 
done, before consensus in the research group was made (appendix I).  
All the SF-36 subscales and the 11 speciﬁc kidney-related scales were 
scored independently and given a score from 0 to 100; a higher score 
indicates a more positive state.  The MCS and PCS scores were standardized 
to a general population mean of 50 and a standard deviation of 10 (i.e. T-
score metric) by using the U.S.-derived scoring algorithm proposed by Ware 
et al (79). Thus a score above or below 50 indicates a state above or below 
average functioning.
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The Beck Depression Inventory 
The Beck Depression Inventory (BDI) self-administered questionnaire was 
applied to measure the level of depressive symptoms (appendix II). BDI has 
been used in both the general and CKD populations (80;81). It consists of 
21 items that examine the somatic and cognitive eﬀects of depression. Each 
item is scored from 0 to 3, where a higher score indicates a higher level of 
depressive symptoms. A BDI score greater than 14 (Paper I), and a BDI score 
greater that 15 (paper II) was used as the cut-oﬀ values for clinical 
signiﬁcant depression in the current study, based on previous reports 
(65;82). A Cognitive Depression Index (CDI) consisting of 15 BDI items was 
generated to evaluate depressive symptoms without including the somatic 
aspects of depression (83).
Ethical considerations
The National Committee for Medical and Health Research Ethics in Norway 
approved the study protocol in June 2005. Concession was obtained from 
the National Data Inspectorate.  Written informed consent after oral and 
written information about the study was a prerequisite for study 
participation. 
The database
An electronic database was constructed on a speciﬁc domain (“Vilje”) of the 
research data server in Oslo University Hospital Ullevål (OUS-U). All data are 
stored in deidentiﬁed form, without patients’ name, date of birth or 
identiﬁcation number. Raw data in paper-form were stored in a double 
locked room, and the cross-code key stored in a diﬀerent location, 
according to the directions given in the permission from the Data 
Inspectorate.  Deidentiﬁed data can be stored until 2025.  Data on only four 
non-sensitive variables could be registered for the eligible patients who did 
not participate in the study: age, gender, modality of dialysis and dialysis 
vintage.
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Statistical methods
Overall statistical methods
In descriptive analyses, clinical, demographic, and HRQOL variables were 
expressed as means and standard deviations (SDs) for symmetrically 
distributed variables, or medians with interquartile ranges (IQR), when data 
were skewed. Normal distributions were assessed by visual inspections of 
histograms. Percentages were used for categorical variables. One-way 
analysis of variance (ANOVA) with post-hoc Bonferroni adjustment, or 
Kruskall-Wallis tests for skewed data were used to compare continuous 
variables among more than two groups, and Student’s t-test or the Mann-
Whitney test for skewed data was applied for comparisons between two 
groups. Chi-square was used to compare categorical variables. For all 
analyses, a signiﬁcance level of 5% was used. The data were analyzed using 
SPSS for Windows version 16 (SPSS, Chicago, IL, USA), except for the 
analysis comparing SF-36 scores between dialysis patients and population 
norms (paper I), for which Number Cruncher Statistical System for Windows, 
2007 version (NCSS, Kaysville, UT, USA) was used.
Reliability measures of the HRQOL and depression scales
A measurement tool is reliable if it consistently provides the same results 
every time a speciﬁc variable is measured. A common test of reliability 
includes homogeneity. Homogeneity testing examines the extent to which 
all the items in a multi-item scale consistently measure a variable. 
Homogeneity, also called internal consistency, was estimated with the 
Cronbach´s alpha coeﬃcient (r). A Cronbachs´s alpha coeﬃcient of 1.00 
equals perfect reliability, whereas a score of 0.00 indicates no reliability.  As 
recommended by Nunnally (84), a Cronbach’s α value of ≥0.70 was used as 
an indicator of adequate internal consistency. For every scale used in the 
current sample, Cronbach’s α coeﬃcient for the internal reliability test was 
calculated. The Cronbach’s α coeﬃcient values from our study are 
summarized in Table 1, together with reported values from Denmark and 
the US (Table 1). Cronbach’s α coeﬃcient for the internal reliability test 
ranged from 0.75 to 0.92 for the eighth generic scales in SF-36. Two of the 
disease-speciﬁc scales had Cronbach’s α coeﬃcient of < 0.70 (“work 
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3status”=0.51 and “quality of social interactions”=0.50). The BDI scale had a 
Cronbach’s α coeﬃcient value of 0.87, in the current sample (n=280).
The two scales ”quality of social interaction” and “work status” did not reach 
the recommended Cronbach’s α value of 0.70 in a test of data from all 
patients in our study. The same ﬁndings were also reported in the reliability 
testing of the Dutch version of KDQOL-SF (19).  Apart from those two 
dimensions, our study demonstrate that the internal consistency reliability 
of the Norwegian version of KDQOL-SF is of the same level as that of the 
original U.S. English version (59). 
31
Table 1.  Internal consistency reliabil
scales of the KDQOL-SF and the gene
ity (Chronba
ric scales o
ch´s α) of
n the SF-3
 the diseas
6 for dialys
e-speciﬁc 
is patients
Cronbach´s α
Scale No of items Danish
versiona
U.S.
versionb
Norwegian
versionc
Disease-speciﬁc scales of the KDQOL-SF
Symptoms and problems 12 0.79 0.84 0.77*
Eﬀects of kidney disease 8 0.71 0.82 0.78
Burden of kidney disease 4 0.85 0.83 0.77
Work status 2 0.72 0.83 0.51
Cognitive function 3 0.81 0.68 0.77
Quality of social interaction 3 0.43 0.61 0.50§
Sexual function 2 0.93 0.89 0.90
Sleep 4 0.83 0.90 0.75
Social support 2 0.67 0.89 0.70
Dialysis staﬀ encouragement 2 0.70 0.90 0.75
Generic scales of the SF-36
Physical function 10 0.93 0.92 0.92
Role limitation due to physical 
problems
4 0.83 0.87 0.86
Bodily pain 2 0.90 0.90 0.86
General health 5 0.77 0.78 0.75
Vitality 4 0.90 0.90 0.83
Social function 2 0.83 0.87 0.80
Role limitation due to emotional 
problems
3 0.79 0.86 0.85
Mental health 5 0.89 0.80 0.82
aData reported by Hays et al (59).
bData reported by Molsted et al (78).
cData from Østhus et al.(74). 
*Only hemodialysis patients included, for
§Cronbach´s α empowered to 0.60 if item
deleted
 PD patients 
 13e (“Did y
Cronbach´s
ou get alon
 α=0.75
g well with other people?”)  
32
Grouping of patients according to age quartiles (paper I)
Anchoring HRQOL measures in population norms makes clinical 
interpretations of HRQOL in diseased patients, more meaningful (77). 
Patients were grouped according to age quartiles (18–49, 50–61, 62–72 and 
73–89 years) instead of age decades, to enhance the sample size in each 
group (Figure 6.7). The SF-36 subscale scores of the age quartile groups, 
were compared with those of appropriate age (by decade)- and gender-
matched population norms (77). 
Multivariate analysis 
In multivariate regression analysis, a mathematical expression is used to 
relate two or more independent variables to an outcome or dependent 
variable. Multiple regression analysis is an extension of a simple regression 
in which an outcome is predicted by a linear combination of two or more 
predictor variables.  In multiple linear regression analysis, the outcome 
variable is a continuous quantity.  A linear regression coeﬃcient indicates 
the impact of each independent variable on the outcome in the context of 
(or “adjusting for”) all other variables. Continuous skewed variables 
(dependent and independent) were log-transformed before being entered.  
To assess relationships between current smoking, HRQOL and depression 
(paper I), linear regression analysis was chosen. Log-transformed BDI, log-
transformed CDI, PCS and MCS scores were set as dependent variables in 
separate multivariate models. Current smoking status was set as an 
independent variable together with all selected covariates.  The impact of 
current smoking status on HRQOL or depression was estimated by its 
regression coeﬃcient in the context of all other selected covariates.  
Unstandardized beta values were estimated with 95% conﬁdence intervals 
(CIs). The interpretations of the beta values (paper I) are diﬃcult, due to 
log-transformation of dependent variables (BDI and CDI). Yet, it was the 
association between smoking and HRQOL or depression that was of 
interest, and whether there are true associations. The magnitude of 
explained variance can be depicted by the R2 values given for the diﬀerent 
models. 
Confounding and selection of covariates (Paper I - III)
A confounding variable can be deﬁned as a variable other that the predictor 
variable in which we are interested, that potentially could aﬀect the 
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3outcome variable. Thus, a potential confounder should be associated with 
both the dependent and the independent variable in a regression analysis. 
Thorough selection strategies for potential confounders (independent 
covariates) were done.  Each independent variable was evaluated for its 
association with the dependent variable (bivariate conﬁrmation). 
Demographic and clinical variables were selected from bivariate analysis if 
they were correlated (p < 0.2) with both current smoking and the 
dependent variable, or if they were considered clinically important. The 
signiﬁcance level was set to 0.2 to avoid losing important factors. 
Multicollinarity occurs when the independent variables in the multiple 
regression equation are strongly linearly correlated. With high correlation 
between independent variables, the quantitative risk estimate for each 
variable maybe imprecise and diﬃcult to interpret (85). Therefore strict 
criteria were followed in the selection process of independent variables. If 
Spearman’s correlation coeﬃcient between two potential confounders was 
outside the interval – 0.70 to 0.70, one of them was excluded (paper I-III). 
Additionally, to avoid that multicollinarity would bias the regression models, 
variance inﬂating factors (VIF) were computed for the covariates 
participating in multivariate analysis (Paper I). The VIF is a measure of 
multicollinearity. A VIF value of >10 is a good reason to worry (86).  The 
maximum VIF value for a participating covariate was 1.92 (paper I). 
Backwards variable selection was then applied to identify the most 
important covariates that remained in the ﬁnal models (Paper I-III).  
Logistic multivariate analysis (Paper II)
In multiple logistic regression analysis, the dependent variable is a 
dichotomous quantity. The risk estimate on the outcome from each 
independent variable in the model is depicted by odds ratio (OR).   
Multivariate logistic regression models were created to investigate the 
relationship between acceptance status for RTX, HRQOL and depression. 
Acceptance status (dichotomized into yes/no) was set as dependent 
variable. MCS, PCS, and BDI scores were set as independent variables in 
three separate regression models. ORs depicting the relationships between 
HRQOL and depression with acceptance status for RTX were calculated. 
Selection of covariates to the regression models was done in similar way as 
in Paper I. 
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Finally a unique multivariate hierarchical regression model was created, to 
see how the ORs changed if diﬀerent sets of independent variables were 
added to the model (paper II). Both the PCS and BDI were included in this 
analysis simultaneously. MCS was let out due to lack of association with the 
dependent variable of interest (acceptance status for RTX).  No signiﬁcant 
interaction between the PCS and the BDI score were observed.  An 
interaction occurs between independent variables if the impact of one 
variable on the outcome depends on the level of another variable. The 
presence of signiﬁcant interaction between two independent variables in a 
multivariate model could bias the risk estimates (ORs). 
To investigate whether HRQOL or depression could predict the likelihood of 
receiving a renal transplant, Cox regression analysis was applied. In 
proportional hazard regression, also known as Cox regression (85), the 
outcome variable is the duration of time to the occurrence of a binary event 
during a follow-up period of observation.  Time from study participation 
(time zero) until renal transplantation (event) was the dependent variable 
(time to event). Each patient´s ﬁnal state at end of follow-up could be 
classiﬁed as either transplanted at a speciﬁc time or as censored if lost to 
follow up or not transplanted (still in dialysis) by the end of follow up. 
Patients were also censored by time of death.  Censoring is a technique for 
incorporating diﬀering lengths of patient follow-up from a longitudinal 
study. The censored patients contribute information only until the time that 
they leave the study. The unadjusted and multi adjusted hazard ratios for 
transplantation during follow-up per unit increase in HRQOL or BDI score 
were estimated with 95% CI. 
Overﬁtting
The hazard ratio may be unreliable if the multivariable data contain too few 
outcome events (transplantation), relative to the number of independent 
variables. In general, the results of models having fewer than 10 outcome 
events per independent variable are thought to have questionable accuracy 
(87). Of the 86 patients with pending transplantation status at study start, 
47 events (transplantations) occurred during follow up (paper II). 
Estimating HRQOL quartile scores (Paper III)
HRQOL component summary scores (PCS-36, MCS-36, PCS-12 and 
MCS-12) were divided into quartiles (paper III). Kaplan-Meier curves, with 
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3log-rank tests, were applied to compare survival rates between groups with 
diﬀerent HRQOL quartile scores. Although HRQOL is considered a 
continuous variable, we implemented quartiles to reveal clinically signiﬁcant 
diﬀerences.  By comparing quartiles, information that may be of clinical 
relevance may emerge more clearly. Lectures by Hosmer DW emphasized 
the utility of applying quartiles (even though symmetrical distributed) to get 
information from the data that may be of clinical interest (oral 
communication from Professor Leiv Sandvik).
Cox proportional hazard models, were used to estimate the unadjusted and 
adjusted hazard ratios (HRs) of death for groups with diﬀerent HRQOL 
quartile scores, and for changes in continuous HRQOL scales by one-unit 
increments (paper III). HRs are presented with 95% conﬁdence intervals. In 
quartile analyses, the upper quartile (best perceived state) was used as the 
reference level. Demographic and clinical variables listed in Table 1 were set 
as independent variables in separate univariate Cox regression analyses to 
identify variables signiﬁcantly associated with death; variables with p <0.2 
were entered into the adjusted Cox regression model as covariates.  
Furthermore, a potential confounder must also be associated with the 
independent variables of interest (PCS-36, MCS-36 and BDI were chosen).  
Thus, the selection of covariates in multivariate Cox-regression analysis 
followed the same strategy as in linear and logistic multivariate regression 
analysis (paper I and II). 
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Results of the papers
Paper I
Overall, both male and female dialysis patients scored signiﬁcantly lower 
than the Norwegian population norms on all SF-36 subscales.  After 
stratiﬁcation for age quartiles, the diﬀerences between dialysis patients and 
the general population were attenuated with increasing age.  In the two 
highest age-quartiles, female patients scored better than males on some 
SF-36 scales relative to normative data.  In female dialysis patients above 
72 years all SF-36 subscales were similar to the norms except the general 
health perception (Table 2A). While male patients above 72 years scored 
signiﬁcantly poorer on seven of eighth SF-36 subscales compared with the 
respective norms (Table 2B).  Complete datasets of all age groups and of 
both gender were not given in paper I, and are therefore reported here 
(Table 2A and 2B).
The mean BDI score for the study patients (n=280) was 11.4±7.9, and the 
median score was 10.0 (Q1 6.0, Q2 15.5). In this study, patients below the 
median age of 62 years scored higher on the BDI that those above (11.5 (Q1 
6.0, Q3 18.0) vs. 9.0 (Q1 6.0, Q3 14.0), p = 0.024), and the prevalence of 
depression was also higher in the youngest group (41.1 % vs. 25.2%, p = 
0.005).  The prevalence of depression, deﬁned as a total BDI score above 
14, was 33.2%, and diﬀered signiﬁcantly between smokers and non-
smokers (52.8 vs. 26.4%, p < 0.001).The PCS score was equally 
compromised in smokers and non-smokers (37.2±10.4 vs. 35.7±10.2, ns.). 
MCS was signiﬁcantly reduced in smokers compared with non-smokers 
(44.1 ± 12.2 vs. 48.7 ± 10.3, p < 0.001). 
Current smoking was independently associated with higher BDI score (data 
log-transformed, unstandardized ß = 0.156, CI 0.008 to 0.305, p = 0.039, 
adjusted R2 = 0.505), as well as with higher CDI score (log-transformed, 
unstandardized ß = 0.146, CI 0.046 to 2.46, p = 0.005, adjusted R2 = 
0.495) and worse score on MCS (unstandardized ß = -4.622, CI –7.544 to –
1.699, p = 0.002), after adjustments for multiple covariates.
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Table 2A. S
females fro
F-36 subscale scores in fema
m the general population
le dialysis patients compared with  age-matched
SF-36 
subscale
Female dialysis patients Female reference population* T-test p -value
Age: 18 – 49 years (n= 32) 40 – 49 years (n=225)
PF 64.4 ± 27.5 88.7 ±17.2 <0.0001
RP 35.8 ± 38.7 83.0 ± 32.9 <0.0001
BP 56.6 ± 30.1 74.4 ± 26.3 <0.001
GH 43.1 ±24.6 79.3 ± 22.9 <0.0001
VT 43.1 ±24.5 58.5 ±21.5 <0.001
SF 67.3 ±28.1 85.7 ±24.7 <0.001
RE 66.7 ± 42.0 84.1 ± 30.7 <0.001
MH 70.5 ±18.9 77.9 ±18.4 <0.05
Age: 50 – 61 years (n=25) 50 – 59 years (n= 181)
PF 41.2 ± 27.4 85.6 ± 16.6 <0.0001
RP 48.0 ± 44.2 77.6 ± 36.2 <0.001
BP 48.0 ± 30.0 73.8 ± 27.1 <0.0001
GH 32.1 ±20.0 74.7 ± 22.4 <0.0001
VT 34.8 ±24.6 62.0 ± 21.0 <0.0001
SF 62.0 ±27.4 86.0 ± 21.3 <0.0001
RE 48.0 ± 44.2 84.3 ± 30.9 <0.0001
MH 67.4 ±19.8 79.5 ± 17.3 <0.01
Age:  62 – 72 years (n=19) 60-69 years (n= 152)
PF 45.0 ± 28.0 70.5 ± 23.3 <0.0001
RP 29.2 ± 43.1 55.3 ± 43.3 <0.05
BP 48.9 ± 35.7 62.6 ± 27.8 Ns
GH 37.9 ±27.3 63.1 ± 25.1 <0.0001
VT 45.0 ±23.3 55.4 ± 22.8 Ns
SF 67.1 ±30.4 81.5 ± 22.7 <0.05
RE 64.8 ± 43.5 74.5 ± 38.5 Ns
MH 74.7 ±21.0 77.9 ± 17.8 Ns
Age: 73 – 89 years (n=26) >70 years (n=117)
PH 44.4 ± 25.9 56.1 ± 27.8 Ns
RP 30.0 ± 42.1 37.0 ± 43.0 Ns
BP 55.2 ± 31.4 59.5 ± 29.0 Ns
GH 52.1 ±21.0 62.5 ± 22.1 <0.05
VT 48.9 ±24.0 50.6 ± 22.9 Ns
SF 65.9 ±28.0 74.1 ± 28.7 Ns
RE 49.3 ± 46.2 59.5± 44.2 Ns
MH 78.7 ±18.7 76.7 ±17.8 Ns
Abbreviatio
BP= Bodily 
due to  emo
*Normative 
ns: PF= Physical function, RP=
pain, GH= General health, VT=
tional problems and MH= Me
data published by Loge et al 
 Role limitation due to physical pr
 Vitality, SF= Social function, RE=
ntal health.
(77)
oblems, 
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Table 2B. S
males from 
F-36 subscale scores in male 
the general population
dialysis patients compared with  age-matched
SF-36 
subscale
Male dialysis patients Male reference population* T-test p -value
Age: 18 – 49 years (n= 42) 40 – 49 years (n=220)
PF 72.2 ± 22.8 91.9 ± 12.3 <0.0001
RP 34.6 ± 39.7 86.4 ± 28.7 <0.0001
BP 61.5 ± 27.0 78.9 ± 25.5 <0.0001
GH 41.9 ±20.9 79.3 ± 21.2 <0.0001
VT 43.9 ±21.2 65.4 ± 21.9 <0.0001
SF 64.0 ±32.0 87.6 ± 20.9 <0.0001
RE 61.0 ± 41.4 89.2 ± 26.0 <0.0001
MH 72.8 ±19.1 80.6 ± 15.8 <0.01
Age: 50 – 61 years (n=48) 50 – 59 years (n= 181)
PF 54.0 ± 28.0 87.2 ± 17.4 <0.0001
RP 25.0 ±38.6 78.0 ± 35.9 <0.0001
BP 55.0 ± 28.6 73.2 ± 25.5 <0.0001
GH 41.3 ±21.2 74.1 ± 22.5 <0.0001
VT 45.3 ±19.4 62.4 ± 21.6 <0.0001
SF 62.0 ±33.1 86.5 ± 24.1 <0.0001
RE 52.1 ±45.6 87.5 ± 27.9 <0.0001
MH 72.3 ±20.4 79.7 ± 16.0 <0.01
Age:  62 – 72 years (n=57) 60-69 years (n= 131)
PF 60.3 ± 25.1 84.3 ± 16.9 <0.0001
RP 25.6 ± 34.6 68.1 ± 43.8 <0.0001
BP 65.7 ± 25.6 70.6 ± 25.4 Ns
GH 46.3 ±23.3 68.0 ± 25.1 <0.0001
VT 43.9 ±22.4 64.7 ± 21.6 <0.0001
SF 68.0 ±24.1 89.3 ± 20.2 <0.0001
RE 57.6 ±42.5 78.6 ± 31.9 <0.001
MH 78.1 ±17.6 81.2 ± 15.8 Ns
Age: 73 – 89 years (n=52) >70 years (n=110)
PH 42.8 ± 25.9 75.0 ± 19.8 <0.0001
RP 13.1 ± 24.1 52.5 ± 43.8 <0.0001
BP 57.7 ± 23.7 69.4 ± 27.4 <0.01
GH 45.7 ±19.0 67.5 ± 22.6 <0.0001
VT 44.7 ±18.9 61.9 ± 21.8 <0.0001
SF 69.7 ±24.7 82.3 ± 23.8 <0.01
RE 40.7 ± 40.6 69.7 ± 37.6 <0.001
MH 77.9 ±13.0 82.7 ± 16.9 Ns
Abbreviatio
BP= Bodily 
limitation 
due to  emo
*Normative 
ns: PF= Physical function, RP=
pain, GH= General health, VT=
tional problems and MH= Me
data published by Loge et al (
 Role limitation due to physical
 Vitality, SF= Social function, R
ntal health.
77)
 problems, 
E= role 
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Paper II
HRQOL and depression in chronic dialysis patients accepted (RTX+, n=122) 
or rejected (RTX-, n=93) for renal transplantation (RTX) were compared. 
Dialysis patients with pending acceptance status (RTX±, n=86) were 
followed for a median time of 3.6 (range 2.8 – 4.5) years to assess whether 
HRQOL or depression predicted the likelihood of receiving a transplant.  
The prevalence of depression (deﬁned as a BDI score >15), and the level of 
depressive symptoms (BDI score), were similar in the three patient groups 
(RTX+: 29.1 % depression, median BDI score: 9.0 (IQR; 5.0-15.3), RTX±: 
28.8 %, BDI score: 10.0 (6.0-16.8), and RTX-: 32.5 %, BDI score 10.0 
(7.0-15.5).  While patients rejected for RTX had signiﬁcantly poorer PCS 
score compared to patients accepted or patients with pending acceptance 
status (RTX+: 40.4 ± 10.1, RTX±: 36.5±10.0, RTX-: 32.4±9.4, p<0.001), 
the MCS score was similar in the three groups (RTX+: 48.0 ± 11.1, RTX±: 
46.5±11.8, RTX-: 47.9±9.8, p=ns). 
However, in multivariate analysis (including patients accepted or rejected 
for RTX), a signiﬁcant association between reduced BDI score (less 
depressive symptoms) and being accepted for RTX emerged. The 
association between higher PCS score (better perceived physical health) with 
being accepted for RTX persisted in multivariate analysis. No association 
between acceptance status and MCS was observed. Less depression and 
better HRQOL (PCS) were associated with being on the waiting list for RTX 
after adjusting for comorbidity, age, gender and dialysis vintage. 
During follow-up, 55 % (n=47) of the dialysis patients in the group with 
pending acceptance were transplanted. The likelihood of receiving a renal 
graft during follow-up in patients with pending acceptance status, was not 
inﬂuenced by PCS (adjusted HR 1.01, 95% CI 0.98 – 1.04), MCS (adjusted HR 
1.00, CI 0.97 – 1.03), or BDI (adjusted HR 1.00, CI 0.96 – 1.05) score, after 
adjustment for age, gender, comorbidity and log-transformed dialysis 
vintage.   Only comorbidity remained an independent predictor for receiving 
a renal transplant. 
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Paper III
Whether HRQOL measured with SF-12 or SF-36 component summary scores 
predicted mortality in dialysis patients was assessed after a median follow-
up of 3.6 years (range 2.8 to 4.5 years). Of the 301 study patients, 21 
patients were excluded from survival analysis due to short observation time 
(< 2 months). Ten patients missed the SF-36 component summary score 
and additionally 18 patients missed the SF-12 component scores, thus data 
from 252 patients were analyzed. At end of follow-up 85 patients (33.7 %) 
had died and 122 patients (48.4 %) had received a renal transplant. The 
most frequent causes of death were cardiovascular disease 42.4% (n=36), 
sepsis 31.8% (n=27), and malignant disease 14.1% (n= 12). Signiﬁcant 
correlations were observed between PCS-36 and PCS-12 (ρ= 0.93, 
p<0.001, n=252) and between MCS-36 and MCS-12 (ρ=0.95, p<0.001, 
n=252).
Compromised PCS-36 was associated with higher age, longer dialysis 
vintage, lower serum albumin, and higher comorbidity score. While reduced 
MCS-36 was associated with younger age, current smoking, and being 
unable to work due to health. In univariate analyses, increased mortality 
was signiﬁcantly associated with higher age, higher comorbidity score, 
current smoking, and longer log-transformed dialysis vintage. No 
associations with dialysis modality, gender, hemoglobin, previous graft 
failure, serum albumin, body mass index, or cholesterol were observed.  
Kaplan-Meier curves showed higher mortality rates for patients in the 
lowest quartiles of PCS-12 (χ2 = 15.3, p=0.002) and PCS-36 (χ2 = 16.7, 
p=0.001). No association between MCS (neither MCS-12 nor MCS-36) and 
mortality was observed. 
During follow-up, patients with the lowest PCS-12 quartile score had a 2.5-
fold higher risk of death compared to patients in the highest quartile (best 
perceived state) after adjusting for age, gender, log-transformed dialysis 
vintage, comorbidity score and albumin. For the PCS-36 quartiles, the 
corresponding diﬀerence in risk was 2.7 after multiple adjustments. 
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4Discussion
Methodological considerations 
Study design
In order to study prevalence’s of HRQOL, depression, clinical and 
sociodemographic characteristics in prevalent dialysis patients, a cross-
sectional design was used. An obvious limitation is that we cannot conclude 
about causality. The results from the present study may serve as reference 
data for future research.  
Bias
In a broad perspective, bias may be deﬁned as any factor or process, which 
tends to produce results or conclusions that diﬀer systematically from the 
truth. More speciﬁcally, selection bias occurs when participants in a study 
diﬀer in a systematic way from the background population. 
Due to the inclusion criteria in the present study, patients with cognitive 
impairment, psychosis and drug abuse could not be included. Furthermore, 
it was a clinical impression during data collection that those patients willing 
to participate in the study presented as healthier than patients refusing. The 
most common reasons for refusing participation were exhaustion and lack 
of motivation. Lack of motivation can also be a symptom of depression. 
Thus, our results concerning HRQOL and depression may be an 
underestimation due to non-response bias. 
Information bias
Answers on questionnaires may be a source of information bias. Patients 
have a tendency to under-report number of daily smoked cigarettes, 
because the question may be perceived as value-laden.  In our study (paper 
I) patients were classiﬁed as smokers or non-smokers, and diﬀerences in 
HRQOL and depression scores were prominent.  
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Internal and external validity of the questionnaires
The Cronbach’s α coeﬃcient for the internal validity was estimated for all 
scales used in the current work. Two of the scales (“quality of social 
interaction” and “work status”) from the KDQOL-SF did not reach the 
recommended level of >0.70 in our data. In accordance with data from 
US(59), Denmark (78), the Netherlands (19) and Japan (88), the scale 
“quality of social interaction” did not reach the recommended value of 
>0.70 . Similarly to the Danish(78) report, the Cronbach’s α value was 
empowered to 0.60 if one of the three items was deleted from the scale 
(Table 1). Also the “work status” scale had a Cronbach’s α coeﬃcient score 
below 0.70 in our data, similar to the Dutch version(19). However, overall, 
the internal validity was high (Table 1), supporting the reliability of the 
instruments used in this cohort of Norwegian dialysis patients. Also the 
distribution curve of BDI in our sample was similar to what has been 
reported in data from the US (89), supporting the validity of this instrument 
within our cohort. 
Our study was carried out in a culturally homogeneous group, as only seven 
of 301 patients were non-Caucasians. The Norwegian dialysis patients are 
characterized by high transplantation rate and thus short time in dialysis 
than what patients from other countries may experience. Our results can 
therefore not necessarily be applied on other populations.   
Case mix
Case-mixing may create a problem in HRQOL studies (45;90). This is 
adjusted for in the statistical analyses. 
Completeness of data
Eﬀorts were made during the data collection to enhance completeness of 
data. Thus, the KDQOL- SF questionnaire was complete for more than 
90.0% of all scale scores, except for two scales “sexual function” and 
“dialysis staﬀ encouragement” for which 55.2 % and 83.4 % were complete.
In SF-36 questionnaires, if there were missing data in half or less than half 
of the items within a scale, the missing values were replaced with the 
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4respondent's mean score across the completed items in the same scale (77). 
The SF-36 was initially scored without substituting missing items, and a 
total of 284 (94%) component summary scores could be calculated. When 
applying the algorithm including substitution of missed items (if < 50% 
missing items within the scale, the missing value was substituted by the 
mean of the other item scores within the same scale in the same patient) 
the number of component summary scores was empowered to 291 (97%). 
The substituted SF-36 scale scores are presented (paper I, II and III). When 
estimating component summary scores, all eight subscales on the SF-36 
had to be included. Thus, the substitution was only done when scoring at 
subscale level. The percentages of missing scale scores on the SF-36 after 
substitution ranged from 1.0 % for physical function and bodily pain, to 
2.3% on the role limitation due to emotional problems, resulting in 291 
physical and mental component summary scores. 
When scoring the SF-12 component summary scores (PCS-12, MCS-12, 
paper III), no substitution was made. The summary scores (SF-12) were 
estimated directly from the 12 items, thus a total of 284 (94%) SF-12 
component summary scores were calculated (http://gim.med.ucla.edu/
kdqol/downloads).  
The BDI was complete on all items in 237 patients (79%). If less than ﬁve 
items of the 21 items in the BDI were missing, these were substituted by the 
most frequent occurring item score from the rest of the study sample. If 
more than 5 items were missing, the patient was excluded. BDI could thus 
be scored in 280 patients (93%).
For the kidney speciﬁc scales in KDQOL, no substitution for missing item 
values was done. Numbers of complete scale scores (KDQOL-SF, BDI) are 
given in parenthesis in the Tables (paper II and paper III).
Selection of study instruments (questionnaires)
Patient-reported measures are a core aspect of health care. But there is 
much to learn about how to use HRQOL instruments in order to improve 
clinical practice (91). In the early nineties it was forecasted that HRQOL 
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questionnaires would become methodologically more sophisticated as well 
as simpler to use and interpret in near future (17). The KDQOL-SF 
instrument is designed to assess psychological and treatment related 
problems speciﬁc to patients in dialysis (50).  The present study we 
assessed HRQOL according to the present recommended procedures by 
applying the KDQOL-SF version 1.3 including both generic and disease 
speciﬁc dimensions (19). In that manner our results could be compared with 
normative data from the general Norwegian population(77), as well as 
speciﬁc kidney related problems could be assessed. Additionally we used 
the SF-12, to assess if this short 12-item questionnaire would perform 
similarly to the longer version SF-36 with regard to predict mortality.  
Discussion of the results
Paper I
Our results show that HRQOL is compromised and clinical signiﬁcant 
symptoms of depression prevalent in Norwegian dialysis patients. Overall, 
both male and female dialysis patients scored signiﬁcantly lower on all 
SF-36 subscales compared with age- and gender-matched norms (paper I). 
The observation that mental aspects of HRQOL were more suppressed 
compared to the age-matched general population in the youngest age 
groups, may reﬂect that younger patients are more vulnerable as they have 
higher expectations with regard to health than elderly. The younger patients 
were also more likely to smoke than elderly patients. We observed that 
smokers had reduced mental health (MCS score) and more depression than 
nonsmokers. The reciprocal relationship between smoking and depression 
is well documented in epidemiological studies (70;92). Our study 
demonstrates this relationship in dialysis patients, as the associations 
between smoking and depression or poor MCS persisted after multiple 
adjustments.  In a regression model with CDI score as dependent variable 
(CDI: a scale evaluating depressive symptoms without including somatic 
symptoms of depression), current smoking, younger age, lower education, 
being divorced/separated, higher comorbidity and poorer scores on eﬀect 
of kidney disease, social support, sleep and symptoms were all 
independently associated with higher CDI score (more depression). 
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4PCS was not worse in smokers vs. non-smokers (37.1±10.4 vs. 35.7±10.2, 
ns), but still both groups had very poor scores. In comparison, an average 
PCS score of 52.9 has been reported for Norwegian general population with 
no self-reported medical condition (44). Contrary to our ﬁndings, a recent 
Danish study including 71 HD and 59 PD patients, found that smoking had 
an independent negative eﬀect on the PCS, while no association with MCS 
was found (71). The authors concluded that physical activity should be 
encouraged, and that information on health eﬀects of smoking and quitting 
smoking techniques should be a natural part of the treatment (71).
Studies assessing non-adherence among dialysis patients have observed 
that up to 60% of dialysis patients do not adhere to neither diet, ﬂuid-
intake nor medication regimen (93). Compliance to medical treatment is of 
crucial importance for outcome in ESRD patients(94), since these patients 
depend on multiple drugs and extensive treatment regime.  Our results that 
negative health behavior like smoking is associated with depression and 
poor mental health, could suggest a need to identify and treat depression in 
order to cope with smoking cessation.  If considering smoking as a sign of 
non-compliance, or as a maladaptive coping strategy to experienced loss 
and burden, well-targeted interventions (depression screening and 
treatment, and/or smoking cessation programs) seem clinical meaningful.  
Based on our results we may hypothesize that if depression is alleviated, 
patients would be better enabled to make better decisions on lifestyle 
changes.  As smoking is a known risk factor for cardiovascular disease in 
ESRD patients, smoking cessation is of great importance to these patients. 
Our study was cross-sectional, and causality cannot be concluded. Clinical 
intervention studies assessing whether treatment of depression may ease 
smoking cessation in dialysis patients is needed.
Paper II
Being accepted for RTX was associated with higher PCS score and fewer 
depressive symptoms.  It is known that renal transplantation is a superior 
alternative to dialysis for ESRD patients (95). Thus, we may interpret our 
ﬁndings that knowing that transplantation is a realistic option has a positive 
eﬀect on patient’s self- perceived HRQOL. We may think that future 
perspectives of better health itself may aﬀect HRQOL positively. This is in 
line with the hypothesis raised by Perneger et al (50), that being accepted 
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for RTX “per se” could aﬀect HRQOL positively. A recent paper published 
after we had reported our data, conﬁrms our ﬁndings that fewer depressive 
symptoms and better HRQOL are associated with being on the waiting list 
for RTX in ESRD patients(96). The latter observation was based on 6383 
prevalent HD patients in the Dialysis Outcomes and Practice Patterns Study 
(DOPPS)(96). The authors conclude though, that low subjective well-being 
may identify patients with reduced access to the waiting list.  And they 
speculate that patients with compromised HRQOL are less likely to get 
access to the transplantation program (96). A causal relationship between 
HRQOL, depression and acceptance status for RTX, can only be answered in 
well-designed longitudinal studies, in which HRQOL data are measured 
repeatedly from the ﬁrst nephrology referral and planning of RRT to 
acceptance for renal transplantation. 
Patients with chronic illness adapt to the disease and the consequences with 
time, even with preserved mental aspects of HRQOL.  Evidence has 
suggested that psychological distress increases as time on the waiting-list 
for RTX increases (97), and decreases after RTX (98).  How time on the 
waiting list can aﬀect HRQOL and prevalence of depression should be 
addressed in future longitudinal studies.   
In the prospective part of this study including 86 prevalent dialysis patients 
with pending acceptance status for RTX neither HRQOL nor depression had 
any eﬀect on the likelihood of receiving a transplant.   Only comorbidity was 
an important contributing factor; low comorbidity score predicted increased 
likelihood for RTX, which would be expected.  These ﬁndings are reassuring 
with regard to the present clinical practice in Norway, implicating that all 
patients have similar possibilities to be transplanted, and only objective 
criteria, e.g. cardiovascular health, limit the possibility.  The eligibility for 
RTX is based on medical factors, and the pre-requisite for organ allocation 
based on ABO and HLA-matching.  Thus our ﬁndings contradict previous 
reports indicating that non-medical factors like gender or psychosocial 
variables limits the access to waiting list and RTX (99-102).  In the recent 
DOPPS study (96), prevalent waitlisted HD patients (n=1838) were followed 
for approximately 1.5 year, and time of RTX registered.  Similarly to our 
results, the likelihood of receiving a renal transplant was not predicted by 
HRQOL or depression. However, it was observed gender and ethnicity 
diﬀerences; the transplantation rate was lower among females and blacks.  
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4In Norway, female gender does not limit the possibility for RTX(13), and 
transplantation in elderly is encouraged (14).
Only patients with pending transplantation status at baseline were included 
in our prospective Cox analysis with regard to likelihood of receiving a RTX. 
This contrasts the DOPPS study (96). Patients already on the waiting list 
were included in the prospective analysis.  When patients are placed on the 
waiting list, it is expected that they eventually will be transplanted, 
therefore, the best way to demonstrate whether psychosocial factors have 
impact on the probability for RTX would be in patients with pending status 
for being on the waiting list.
Finally, the ﬁnding that poor HRQOL, as measured with PCS and higher level 
of depressive symptoms were associated with being permanently rejected 
for RTX should draw attention to the clinical challenges posed by that 
decision. How can clinicians oﬀer optimal medical care to patients 
permanently rejected for RTX, and facing life-long dialysis? How can HRQOL 
be improved or at least maintained?  Clinical depression should be focused 
on in patients rejected for RTX.  
Paper III
HRQOL measured with the PCS is an independent predictor of mortality in 
dialysis patients, whether using the short (PCS-12) or the full-length 
(PCS-36) version of the SF-36 questionnaire. 
Our data has shown that the PCS-12 is a strong and independent predictor 
of death in dialysis patients during a median follow-up of 3.6 years. The 
diﬀerent mortality rates between the PCS-12 quartiles (n=252) diverged 
step-wise (Kaplan-Meier plots, paper III).  Patients in the 3rd PCS-12 quartile 
had 1.7 higher multi-adjusted hazard ratio of death, and patients in the 2nd 
PCS-12 quartile had a 2.4 higher multi-adjusted hazard of death compared 
with the highest quartile (best perceived state) during follow-up. Patients in 
the lowest PCS-12 quartile had a 2.5 higher hazard ratio of death during 
follow-up, compared with those in the highest quartile after adjusting for 
age, gender, comorbidity score, dialysis vintage and albumin. The 
questionnaire (SF-12) is easy to ﬁll out (it consist of 12 items), and not very 
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time consuming. Based on our result, we suggests that the PCS-12 score 
(from SF-12) could be used repeatedly as a risk estimate in dialysis 
patients, just as the level of serum albumin is measured monthly. Based on 
our ﬁndings, SF-12 seems to be a valid tool for risk estimation in dialysis 
patients.  Previous studies have compared the predicative eﬀect of HRQOL 
on mortality with the traditional risk factor albumin, and in the large DOPPS 
study, it was observed that a 10-point lower PCS score (based on the SF-36) 
was associated with increases in the risks of death and hospitalization that 
were greater than the corresponding increases in the risks associated with 1 
g/dL (10 g/L) lower serum albumin level (24). In our study we adjusted for 
albumin in the multivariate analysis. 
The MCS-12 or the MCS-36 did not aﬀect mortality in our data. In general, 
the reduction of HRQOL scores with norms in ESRD patients is greater for 
physical than for mental health (27;103).   It has been suggested, that the 
impact of chronic disease on aspects of self-assessed mental health may 
become blunted with time, due to psychological adaptation (40). In this 
perspective, it may be that when studying prevalent dialysis patients, the 
eﬀect of MCS on mortality could be blunted.  Based on present literature, we 
would expect that both presence of depression or high level of depressive 
symptoms as measured by the BDI, as well as poor MCS score from SF-36, 
potentially could have negative impact on survival in dialysis patients. In a 
study of 294 ESRD patients treated with HD, Kimmel et al reported that, the 
level of depressive aﬀect measured by the BDI was signiﬁcantly associated 
with mortality, when depression was treated as a time-varying covariate 
based on periodic follow-up assessments and using multiple, pooled 
measurements of depression (89).  While, patients´ baseline level of 
depression was not a signiﬁcant predictor of mortality at 38.6 months of 
follow-up (89), in accordance with our present ﬁndings. Similarly, in a more 
recent study, Boulware et al. (104) assessed data from the Choices for 
Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study, a 
large observational follow-up study in the US, levels of depression at the 
beginning of the study was not associated with increased overall mortality 
risk, but with several diﬀerent time-dependent analyses they could conﬁrm 
that persistently high levels of depressive aﬀect over time were associated 
with death (104).   In our study, we were limited to study associations 
between self-assessed mental health at study inclusion, with survival after a 
median follow-up of 3.6 years.  Longitudinal studies with repetitive 
measurements of HRQOL and depression should be done, in order to 
understand mechanisms underlying the relationship between depression 
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and survival, and the eﬀect of treatment of depression in dialysis patients. It 
also emphasizes the importance of repeatedly using questionnaires to 
identify HRQOL and depressive symptoms in dialysis patients in order to 
intervene in high-risk individuals. 
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Conclusions
•    Reduced HRQOL and high level of depressive symptoms are present in 
Norwegian dialysis patients (paper I). 
•    Poor mental health and higher level of depressive symptoms are 
associated with current smoking in chronic dialysis patients (paper I).
•    Compromised HRQOL and higher level of depressive symptoms are 
associated with being rejected for RTX in dialysis patients (paper II). 
•    The HRQOL and level of depressive symptoms did not predict the 
likelihood of RTX in dialysis patients. Only the comorbidity had impact on 
probability of RTX (paper II).
•    HRQOL strongly predicts mortality in patients on chronic dialysis, 
after adjustments for traditional risk factors.  The PCS score from the SF-36 
provided comparable results as the PCS score from the shorter SF-12 (paper 
III). 
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5Clinical implications of thesis
•    Our ﬁnding that HRQOL is substantially suppressed in Norwegian 
dialysis patients relative to normative data from the general population, 
point to the urgent need to increase and possible improve supportive care 
to this growing patient population. 
•    Our results highlight the importance of routinely HRQOL assessments 
in clinical practice. HRQOL measurements are important in order to gain 
information about clinical status and well-being, and to identify patients at 
risk of poor outcome. The assessments can enable adjustment of care 
according to individual patients needs. 
•    Our ﬁnding that younger dialysis patients are more susceptible for 
depression than older patients, should aware clinicians that diﬀerent sub-
groups of patients may have diﬀerent needs regarding symptom 
assessment and treatment. 
•     Routinely screening for depression in dialysis patients is needed, in 
order to identify patients that may have beneﬁt on other types of treatment. 
Inter-disciplinary cooperation between nephrologists and consultation-
liaison psychiatrists should be encouraged. 
•     Because the SF-12 requires less time to complete than the SF-36, it 
could be a feasible instrument to apply in routinely HRQOL assessments, in 
addition to other, more traditional, risk factors. We suggest the PCS-12 to 
be assessed regularly in dialysis patients. 
•    Physical exercise programs in dialysis should be encouraged, as the 
physical aspects of HRQOL (PCS) were so substantially suppressed in our 
study. There are no such oﬀers for dialysis patients in Norway, contrary to 
patients with chronic pulmonary diseases and cancer patients. There is no 
reason that ESRD patients should be left in physical inactivity. 
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Future research
Not only do we need easily accessible tools to diagnose reduced HRQOL and 
estimate risk, but also we need to know more about treatment options in a 
particularly vulnerable patient group characterized by high comorbidity. We 
do not only need longitudinal study on HRQOL and depression in dialysis 
patients, but also randomized controlled trials of therapy aimed at 
modiﬁable risk factors such reduced mental health and low HRQOL. We 
need to highlight causality rather than associations as many researchers 
previously have pointed out.  Be that as it may, it is important to assess how 
patients adapt to ESRD during time, and to identify possible vulnerable 
phases where patients may be in need of enhanced supportive care. Our 
prevalent data cannot give information about that. 
Suggestions for future research based on the thesis:   
•    Regular and repeated assessment of HRQOL in incident dialysis 
patients in order to assess how HRQOL evolves during time. 
•    Clinical intervention studies to investigate whether treatment of 
depression may improve HRQOL and ease smoking cessation in dialysis 
patients.
•    Follow-up studies to investigate whether RTX translates into further 
improvement of HRQOL and less depression. 
•    Assess whether time on the waiting list can aﬀect HRQOL and 
prevalence of depression in dialysis patients.
•    Follow-up studies assessing the impact of depression and impaired 
HRQOL on graft survival after RTX, and whether graft function will aﬀect 
HRQOL.
•    To describe HRQOL in diﬀerent subgroups of dialysis patients, to 
identify patients at particular risk of compromised HRQOL.  
•    Longitudinal studies with repetitive measurements of depression, in 
order to understand mechanisms underlying the relationship between 
depression and survival. 
•    Controlled clinical trails to assess if physical training programs would 
improve the physical composite scores of either SF-12 or SF-36.
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5Summary of thesis
The current study has demonstrated that HRQOL in Norwegian dialysis 
patients was signiﬁcantly poorer than in the general population, and that 
the prevalence of clinical signiﬁcant symptoms of depression was high. 
Compromised HRQOL and high level of depression were particularly 
prominent in the youngest age group (patients from 18 to 62 years). 
Current smoking was associated with reduced mental aspects of HRQOL and 
more depression. While, physical health was equally compromised in 
smokers and non-smokers.  Patients on the waiting list for renal 
transplantation reported better physical HRQOL and less depression than 
patients rejected for renal transplantation, irrespectively of comorbidity and 
age. The likelihood of receiving a renal transplant in Norwegian dialysis 
patients was not predicted by psychosocial factors, but by the level of 
comorbidity. Reduced self-reported HRQOL is a strong and independent 
predictor of mortality in Norwegian dialysis patients. The results from our 
study highlight that reduced HRQOL and high prevalence of depression in 
dialysis patients cannot be ignored in clinical practice, and that both issues 
should be addressed in proper intervention clinical trials, as potential 
modiﬁable risk factors. 
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6Erratum list
In final proofing of Paper III, following corrections was executed:
Correction 1:
In the title a c was changed to a capital C. Correct tiltle: Mortality and health-
related quality of life in prevalent dialysis patients: Comparison between 12-
items and 36-items short-form health survey
Correction 2:
Table 1,
Range: 9.6 - 30.1 was changed to 9.6 - 30.0
Range: 44.4 - 58.2 was changed to 44.5 - 58.2
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Mortality and health-related quality of life in
prevalent dialysis patients: Comparison between
12-items and 36-items short-form health survey
Tone Brit Hortemo sthus1,2*, Valjbona Tiric Preljevic2,3, Leiv Sandvik2,4, Torbjørn Leivestad5, Inger Hilde Nordhus6,7,
Toril Dammen2,3 and Ingrid Os1,2
Abstract
Background: To assess health- related quality of life (HRQOL) with SF-12 and SF-36 and compare their abilities to
predict mortality in chronic dialysis patients, after adjusting for traditional risk factors.
Methods: The Short-Form Health Survey (SF-36) with the embedded SF-12 was applied in 301 dialysis patients
cross-sectionally. Physical and mental component summary (PCS-36, MCS-36, PCS-12, and MCS-12) scores were
calculated. Clinical and demographic data were collected. Mortality (followed for up to 4.5 years) was analyzed with
Kaplan Meier plots and Cox proportional hazards, after censoring for renal transplantation. Exclusion factors were
observation time <2 months (n = 21) and missing component summary scores (n = 10 for SF-36; n = 28 for SF-12),
thus 252 patient were included in the analyses.
Results: In 252 patients (60.2 ± 15.5 years, 65.9% males, dialysis vintage 9.0, IQR 5.0-23.0 months), mortality during
follow-up was 33.7%.(85 deaths). Significant correlations were observed between PCS-36 and PCS-12 (ρ= 0.93,
p< 0.001) and between MCS-36 and MCS-12 (ρ= 0.95, p< 0.001). Mortality rate was highest in patients in the
lowest quartile of PCS-12 (χ2 = 15.3, p= 0.002) and PCS-36 (χ2 = 16.7, p= 0.001). MCS was not associated with
mortality. Adjusted hazard ratios for mortality were 2.5 (95% CI 1.0-6.3, PCS-12) and 2.7 (1.1 – 6.4, PCS-36) for the
lowest compared with the highest (“best perceived”) quartile of PCS.
Conclusion: Compromised HRQOL is an independent predictor of poor outcome in dialysis patients. The SF-12
provided similar predictions of mortality as SF-36, and may serve as an applicable clinical tool because it requires
less time to complete.
Keywords: Chronic kidney disease, Dialysis, Health-related quality of life, Mortality, Physical component summary
score, SF-12 and SF-36
Introduction
Despite advances in dialysis treatment and improvements
in the management of traditional cardiovascular risk fac-
tors, mortality rates for patients with end-stage renal dis-
ease (ESRD) on chronic dialysis remain unacceptably high.
For patients with ESRD in Europe and the United States,
survival rates after initiation of dialysis treatment are 81.1%
and 80.4%, respectively, at one year and 38.2% and 35.8%,
respectively, after five years [1,2]. The established predictors
of mortality in patients on dialysis include low serum albu-
min [3], hemoglobin [4], and increasing age [5]. In addition,
patients rejected for renal transplantation are at special risk
for lethal outcome [6]. Studies have suggested that high
mortality rates might be reduced by improving the quality
of dialysis, control of phosphates, normalization of serum
albumin, and correction of renal anemia [7-9]. However,
despite data that indicates that these quality measures in
dialysis are improving, mortality rates have not improved in
parallel [10].
Recent studies have suggested that a poor health-related
quality of life (HRQOL) was strongly related to increased
risk of mortality in patients on dialysis [11-17]. Thus,
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although HRQOL is typically used to gain information
about patient well-being, it may also indicate the risk of
important outcomes, like death.
The medical outcome survey Short Form 36 (SF-36)
has been widely used and validated as an HRQOL assess-
ment tool in general populations and in patients with
ESRD [11,12,18,19]. SF-12, a shortened version of the SF-
36 questionnaire has recently been introduced, but it has
been rarely used for patients on dialysis, despite the advan-
tage that it comprises only one third of the items com-
pared to SF-36 [20]. The SF-12 was recently employed in a
U.S. study on a large cohort of 44 395 patients on dialysis.
Those authors concluded that the physical (PCS) and
mental composite summary (MCS) scores based on the
SF-12 were valid in this patient group. Furthermore, they
showed that the prognostic information with regard to
mortality was similar to that of the SF-36 [21]. To the best
of our knowledge, the SF-12 has not been specifically
validated in Europe for patients on dialysis; nor has any
European study examined whether the SF-12-based
HRQOL scores might be predictive of mortality. As the
self-perceived HRQOL has been shown to diverge be-
tween countries, it is important to undertake studies of
HRQOL in different countries. We suggest that the com-
ponent summary scores from SF-12 and SF-36 are highly
correlated. Furthermore, we hypothesized that self-assessed
HRQOL based on the SF-12 and the SF-36 would provide
similar predictions of mortality in patients on dialysis.
The objectives of the present study were to assess
HRQOL with SF-12 and SF-36 and compare their abil-
ities to predict mortality in chronic dialysis patients, after
adjusting for traditional risk factors.
Methods
Study patients and design
In this observational prospective cohort study, the primary
aim was to determine the association between HRQOL
and mortality. We included a total of 301 prevalent dialysis
patients (243 on hemodialysis and 58 on peritoneal dialysis)
from ten dialysis clinics in Norway. Baseline HRQOL data
were previously reported [22]. All adult patients (≥18 years
old) that had received hemodialysis (HD) or peritoneal dia-
lysis (PD) for more than 2 months were screened for
study participation. Patients were excluded from the
study when they were hospitalized during the investiga-
tion period; however, they could be enrolled four weeks
or more after hospital discharge, if they were in stable
clinical condition. Patients were excluded that displayed
severely impaired cognitive function, psychosis, or drug
abuse. The study required adequate Norwegian language
skills. Signed informed consent was required for enroll-
ment, after patients received oral and written information
about the study. Detailed information regarding mortality
and cause of death was obtained from the Norwegian
Renal Registry. Patients were enrolled in the study from
August 2005 to February 2007, and they were followed
until January 2010. The recruitment process was described
in detail previously [22]. Briefly, of the 416 patients consid-
ered eligible for the study, 326 patients consented to study
participation, and 301 could be enrolled (enrollment rate
of 72.4%). Patients with observation time less than 2 months
were excluded from the survival analyses (Figure 1), and
the time of renal transplantation was censored. To ensure
standardized conditions, self-administered questionnaires
were completed during the regular hemodialysis sessions
for patients on HD or during the scheduled visit at the
outpatient clinic for patients on PD. Study nurses and
physicians were specifically trained in applying the study
instruments.
The National and Regional Committees for Research
Ethics in Norway approved the study protocol, and permis-
sion was obtained from the National Data Inspectorate.
Demographic and clinical data at baseline
Demographic data including age, gender, and work status
were collected from reviews of hospital charts and/or by
directly questioning the patients. The cause of renal failure,
dialysis modality, dialysis vintage, comorbidities, and labora-
tory data were gathered from medical records. Comorbidity
was measured with the modified Charlson comorbidity
index (CCI) [23]. The CCI is a composite score of 17 mul-
tiple comorbid conditions (e.g., coronary artery disease and
congestive heart failure) and age. In this study, CCI was
N=301
Patients enrolled in the HRQOL 
in dialysis study
N=280
Meeting inclusion criteria
N=21
Excluded
Observation time <2 mo
N=270
Scorable SF-36 component
N=10
Missing component summary-36 
scores
N=252
Scorable SF-12 component 
summary scores
N=18
Missing component summary-12 
scores
summary scores
Figure 1 Participant flow-chart.
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calculated without age, because we intended to evaluate the
effect of age as a separate factor in the multivariate analysis.
Assessment of HRQOL
The Medical Outcome Study 36-item Short-Form health
survey (SF-36) [18] was applied to assess the general
dimensions of HRQOL. A validated Norwegian version
of the SF-36 version 1 was applied [24]. The physical
component summary (PCS-36) and the mental compo-
nent summary (MCS-36) scores were derived from eight
SF-36 subscales, as described by Ware et al. [25]. These
scores ranged from 0 to 100, where a higher score repre-
sented better self-assessed health. The embedded SF-12
comprises 12 questions from the SF-36, and the compo-
nent summary scores of SF-12 were calculated with the
algorithm from the KDQoL working group (http://gim.
med.ucla.edu/kdqol/downloads). The PCS-36 and PCS-
12 included physical functioning, physical role limitation,
and bodily pain; the MCS-36 and MCS-12 included mental
health, social functioning, and emotional role limitation.
General health and vitality were incorporated in all compo-
nent summary scores. Recent reports showed strong corre-
lations between the PCS-36 and PCS-12 and between
MCS-12 and MCS-36 in patients with ESRD [21].
Statistical analyses
Clinical, demographic, and HRQOL variables were expressed
as means and standard deviations (SDs), or medians with
interquartile ranges (IQR), when data were skewed. Cat-
egorical variables were measured as frequencies and per-
centages. The one-way analysis of variance (ANOVA) or
Kruskall-Wallis tests for skewed data were used to com-
pare continuous variables between more than two groups;
the Student’s t-test or the Mann–Whitney test for skewed
data was applied for comparisons between two groups.
The chi-square test was used to compare categorical vari-
ables. HRQOL component summary scores (PCS-36,
MCS-36, PCS-12 and MCS-12) were divided into quartiles,
with equal number of patients in each quartile group
(n=63). Although HRQOL is considered a continuous
variable, we implemented quartiles to reveal clinically sig-
nificant differences. Kaplan-Meier curves were applied to
compare survival rates between groups with different
HRQOL quartile scores. Cox proportional hazard models
were used to estimate the unadjusted and adjusted hazard
ratios (HRs) of death for groups with different HRQOL
quartile scores, and for changes in continuous HRQOL
scales by one-unit increments. HRs are presented with 95%
confidence intervals. In quartile analyses, the upper quar-
tile (best perceived state) was used as the reference level.
All demographic and clinical variables listed in Table 1
were set as independent variables in separate univariate
Cox regression analyses to identify variables significantly
associated with death; variables with p <0.2 were entered
into the adjusted Cox regression model as covariates.
Spearman’s correlations were performed to determine
associations between the demographic and clinical vari-
ables and HRQOL component summary scores (PCS-36
and MCS-36). When a variable was significantly associated
(p< 0.2) with both death and the PCS-36 or MCS-36
score, it was considered a potential confounder. When the
Spearman’s correlation coefficient between two potential
confounders was outside the interval −0.70, 0.70, one was
excluded.
Figure 2 Scatter plots display correlations between physical
and mental component summary scores (PCS and MCS,
respectively). The scores were calculated from the SF-12 (ordinate)
and SF-36 (abscissa) assessments of health related quality of life in
patients on chronic dialysis (n = 252).
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To identify the most important covariates, all selected
variables were entered into multivariate linear regression
models with PCS-36 and MCS-36 as dependent vari-
ables. By backward variable selection, only variables with
p <0.1 were analyzed further.
Age, dialysis vintage, and the Charlson comorbidity
index were included in the final model as covariates. Due
to the selection criteria, serum albumin was included in
the model that examined the relationship between death
and the PCS-36 or PCS-12 quartile score. Hemoglobin
was included in the model that examined the relation-
ship between death and the MCS-36 or MCS-12 quartile
score. Gender was included as a covariate in the final
model, despite the lack of significant associations with
death. When a variable markedly deviated from a normal
distribution, data were log-transformed (e.g., dialysis vin-
tage) before inclusion into the regression model as a cov-
ariate [26].
The significance level was set to 5%. The data were ana-
lyzed with SPSS for Windows, version 16 (SPSS, Chicago,
IL, USA).
Results
Of the 301 patients enrolled in the study, 21 patients
were excluded from the survival analysis due to short ob-
servation time (< 2 months). Ten patient SF-36 compo-
nent summary scores were missing, and additionally 18
patient SF-12 component summary scores. Thus, data
from 252 patients was analyzed (Figure 1). The follow-up
time ranged from 2.8 to 4.5 years, with a median of
3.6 years (IQR 3.2 to 3.9). The time from study inclusion
to death or kidney transplantation ranged from 0.2 to
4.3 years, with a median time of 1.5 years (IQR 0.9
to2.7). At the end of follow-up, 85 (33.7%) patients had
died, and 122 (48.4%) patients had received a renal
transplant.
Highly significant correlations were observed between
the PCS-36 and PCS-12 (r = 0.932, ρ=0.928, p <0.001 for
both, n = 252, Figure 2), and between the MCS-36 and
MCS-12 (r = 0.953, ρ=0.951, p <0.001 for both, n = 252,
Figure 2).
Characteristics of the patients, grouped by quartiles of
PCS-36 and MCS-36, are presented in Table 1. For the
Table 2 Impact of demographic and clinical variables on mortality in chronic dialysis patients (n = 252) during follow-
up (median follow-up time 3.6 years), univariate associations are shown
Hazard ratio 95% CI p-value
Age, per year increment 1.026 1.009 – 1.044 0.002
Gender, male vs female 1.209 0.768 – 1.901 0.412
Currents smoking, yes vs no 1.772 1.125 – 2.790 0.014
Work status
Able to work, yes vs no 0.510 0.186 – 1.398 0.191
Disable to work, yes vs no 1.030 0.659 – 1.610 0.896
Retired, yes vs no 1.162 0.743 – 1.819 0.510
Cause of renal failure
Glomerulonephritis, yes vs no 1.015 0.571 – 1.804 0.959
Diabetic nephropathy, yes vs no 1.704 0.987 – 2.942 0.056
Hypertensive kidney disease, yes vs no 1.147 0.723 – 1.821 0.560
Clinical variables
Dialysis vintage, per month increment 1.009 0.998 – 1-020 0.095
Log-dialysis* vintage, per unit increment 1.284 1.041 – 1.585 0.020
Previous graft failure, yes vs no 1.748 0.926 – 3.299 0.085
Rejected for renal transplantation, yes vs no 1.965 1.063 – 3.635 0.031
Dialysis modality, hemodialysis vs. peritoneal dialysis 1.091 0.632 – 1.883 0.755
Body mass index, per unit (kg/m2) increment 0.985 0.939 – 1.034 0.536
Albumin, per unit (g/l) increment 0.978 0.937 – 1.012 0.176
Hemoglobin, per unit (g/dl) increment 0.879 0.758 – 1.019 0.088
Cholesterol, per unit (mmol/l) increment 0.937 0.747 – 1.176 0.574
Diabetes, yes vs no 1.579 1.002 – 2.487 0.049
Charlsons modified comorbidity index without age, per unit increment 1.260 1.136 – 1.398 <0.001
*Log-transformed dialysis vintage.
Abbreviations: CI confidence interval.
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whole study population (n=252), the mean scores for
PCS-36 was 36.6 ±10.4 (range 9.6 - 58.2), the MCS-36 was
47.3 ±11.0 (16.9 -70.7), PCS-12 was 35.5± 9.9 (13.3 – 56.6),
and MCS-12 was 46.9 ±10.9 (16.7 -70.4). Age, dialysis vin-
tage, serum albumin, and comorbidity differed between
PCS-36 quartiles; age, smoking, and workability differed
between MCS-36 quartiles (Table 1).
The most frequent causes of death were cardiovascular
disease 42.4% (n=36), sepsis 31.8% (n=27), and malignant
disease 14.1% (n=12). Withdrawal from dialysis occurred
in 4.7% (n= 4). In univariate Cox regression analyses
(Table 2), mortality was significantly associated with age,
current smoking, log transformed dialysis vintage, being
rejected for renal transplantation, presence of diabetes
and comorbidity score. In contrast, mortality was not
associated with gender, dialysis modality, hemoglobin,
previous graft failure, serum albumin, body mass index,
or cholesterol.
Figure 3 Kaplan-Meier plots of mortality rates in quartiles (Q1-Q4) of physical (left, PCS) and mental (right, MCS) component summary
scores. Scores were calculated with the SF-36 (n = 252, upper panels) or SF-12 (n = 252, lower panels) assessments in patients on chronic dialysis.
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Mortality rates were significantly different in the highest
and lowest PCS-12 quartiles, based on the Kaplan Meier
curves (Figure 3). A similar difference was observed for
PCS-36 quartiles (Figure 3). In contrast, mortality rates
were not different between quartiles for either the MCS-
36 or MCS-12 (Figure 3, Table 3).
The unadjusted and multi-adjusted hazard ratios of death
were assessed for SF-12 and SF-36 quartile scores (Table 3).
After multiple adjustment, for the PCS-12, patients with
the lowest quartile score had a 2.5-fold higher risk of death
compared to patients in the highest quartile i.e., the best
perceived state. For the PCS-36 quartiles, the correspond-
ing difference in risk was 2.7 after multiple adjustments.
The unadjusted and multi-adjusted HRs of death were
also assessed for continuous SF-12 or SF-36 component
summary scores (Table 4). During the follow-up, a one-
unit increase in the PCS-12 score was related to 3.2% lower
adjusted HR of death; a one-unit increase in the PCS-36
score was related to 2.3% lower adjusted HR of death.
Discussion
We found that poor self-assessed physical health was an in-
dependent predictor of mortality in Norwegian patients on
dialysis, after adjusting for established risk factors. This was
consistent with results previously shown in other popula-
tions [11-14]. Beyond the confirmatory observation that low
self-perceived physical aspect of HRQOL score is associated
with higher risk of death, our results expand that finding that
SF-12, as well as SF-36 revealed the increased mortality risk.
In our study, one unit increase in PCS-12 score predicted
3.2% decreased adjusted HR of death, and one unit of in-
crease in PCS-36 score 2.3% decreased adjusted HR of death.
The great advantage of using SF-12 is that it comprises fewer
items, it is less time-consuming, and easier to use, and thus,
may represent a more clinically applicable tool for monitor-
ing HRQOL. The latter observation was in accordance with
the recent US study reporting that each incremental PCS-12
and PCS-36 point was associated with a 2.4% lower adjusted
HR of death during a one year follow-up [21]. In our study,
the adjusted HR of death was tripled, in patients in the
lowest PCS-12 quartile compared to those in the highest
quartile over the three to four-year period. The findings
support the concept that a poor self-assessed HRQOL is
an important risk factor for death, and it should not be
ignored. Thus, measurement of HRQOL should be
included in the general clinical work-up and follow-ups
of patients on dialysis.
In contrast to some [12,13,15], but not all [11,16] other
studies, we did not find any significant association between
self-assessed mental health and mortality. Although we
observed 1.1% reduction in the hazard ratio of death for
every one-unit increase in MCS-12, this was not statisti-
cally significant. However, the magnitude was consistent
with the 1.2% reduction in the adjusted hazard ratio of
death recently reported by a large US study on patients on
chronic dialysis [21]. The sample size in our study was
most likely too small to reveal a significant relationship
between death and MCS. Conflicting results have been
reported in the literature on the effect of mental health
on mortality. Nevertheless, the mental health effect has
consistently been less than the effect of self-perceived
physical health. Although the level of self-perceived mental
health in the general population may differ among coun-
tries, the MCS scores in the large US study population
[21] were similar to the MCS in our study population,
and they observed that MCS as well as PCS predicted
mortality. In this study, we excluded patients with cogni-
tive disturbance, psychosis or drug-abuse. This exclu-
sion may have affected the level of self-perceived mental
health in our population, and could have led to a lower
likelihood of predicting mortality. In at least some stud-
ies, a poor MCS score has been related to higher levels
of depression, and depression has been shown to predict
mortality in patients on chronic dialysis [27,28].
Table 3 Unadjusted and multi-adjusted hazard ratios (HRs) for mortality were assessed for patients on dialysis,
grouped by physical and mental component summary (PCS-36, MCS-36, PCS-12, and MCS-12) quartile scores
PCS-36 quartile score MCS-36 quartile score
Unadjusted HR(95% CI) p-value AdjustedA HR (95% CI) p-value Unadjusted HR(95% CI) p-value AdjustedB HR(95% CI) p-value
Q4 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q3 3.516(1.508, 8.196) 0.004 2.495(1.041, 5.976) 0.040 1.720(0.911, 3.249) 0.095 1.262(0.616, 2.584) 0.525
Q2 2.599(1.104, 6.119) 0.029 1.741(0.721, 4.205) 0.218 1.634(0.857, 3.115) 0.136 1.460(0.735, 2.898) 0.280
Q1 4.547(2.016, 10.259) <0.001 2.675(1.126, 6.355) 0.026 1.365(0.698, 2.667) 0.363 1.676(0.845, 3.327) 0.714
PCS-12 quartile score MCS-12 quartile score
Q4 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q3 2.248(0.932, 5.423) 0.072 1.658(0.630, 4.365) 0.306 1.262(0.616, 2.584) 0.525 1.671(0.859, 3.250) 0.130
Q2 3.618(1.584, 8.263) 0.002 2.423(0.964, 6.087) 0.060 1.460(0.735, 2.898) 0.280 1.746(0.907, 3.61) 0.095
Q1 4.056(1.789, 9.194) 0.001 2.512(1.009, 6.254) 0.048 1.676(0.845, 3.327) 0.140 1.901(0.978, 3.368) 0.058
sthus et al. Health and Quality of Life Outcomes 2012, 10:46 Page 7 of 9
http://www.hqlo.com/content/10/1/46
As suggested by Ware et al. [29], the use of SF-12, either
interspersed within the SF-36, or on its own, has shown ex-
cellent correlations to the SF-36. The strong correlations that
we observed between the SF-12 and SF-36 summary scores
were consistent with findings in the general Norwegian
population [30]. A recent cross-validation of the selected
items for SF-12 was conducted in nine European countries;
this led to the conclusion that data from the SF-12 were
comparable to standard benchmarks [30]. Thus, our data ex-
tend that finding to include patients on chronic dialysis.
Some clinical and demographic characteristics of our
study population were notable. The prevalence of diabetes
in our study population was 26%, which is lower than that
reported in other HRQOL studies; e.g., 66% was reported
in the Spanish CALVIDA study [15], and nearly 50% was
reported in a recent US study [21]. Diabetes has been a
less prevalent cause of renal disease in Norwegian patients
with ESRD compared to US patients on chronic dialysis
[31]. Furthermore, in our study, the patients had under-
gone regular dialysis over a shorter period than that
reported in other studies [15,21]. This was due to the high
renal transplantation rate in Norway [32,33].
Strengths and limitations of the study
One of the strengths of this study was that the sample was
fairly large; it comprised close to one-third of the total
population on regular dialysis in Norway at the time of
sample selection [34]. In addition, the participation rate in
the health survey was high, and none was lost to follow-
up. The multi-center design ensured inclusion of patients
from both rural and urban areas. Furthermore, socioeco-
nomic status did not affect the possibility of dialysis. The
characteristics of our patient population were quite similar
to those of the general Norwegian population of patients
on dialysis [34] in age, gender, and cause of renal failure.
However, a selection bias could not be excluded, because
the healthiest patients, both physically and mentally, might
be more likely to participate in the study. Our data may
underestimate the effect of HRQOL on clinical outcome,
as patients with psychosis, drug abuse, cognitive distur-
bances, or recent hospitalization due to serious medical
conditions were excluded. In this study we were com-
mitted to use the SF-36 version 1, in order to compare
our results with Norwegian reference population [22,24].
Complete component summary scores could not be calcu-
lated for 10 patients in the SF-36 and for an additional 18
in the SF-12, due to missing single items. Only seven of
the 301 patients were non-Caucasians; thus, the results
may not be applicable to other populations. Furthermore,
the renal transplantation rate in Norway is among the
highest in Europe [32,35]. This affected the total time
spent on chronic dialysis. During follow-up, 47% of patients
received a kidney transplant in this study.
Conclusions
Self-assessed physical health based on either the PCS-12
or PCS-36 is a strong, independent predictor of mortality
in patients on chronic dialysis. The PCS-12 and PCS-36
provided comparable results. Thus, the physical aspects of
HRQOL may increase the accuracy of risk stratification by
adding important prognostic information for patients on
dialysis. We suggest that the HRQOL assessment should
be included in clinical investigations. Because the SF-12
requires less time to complete than the SF-36, it should be
used routinely to assess HRQOL, in addition to the trad-
itional, risk factors. It remains to be determined whether
specific interventions aimed to improve HRQOL would
affect the composite scores of either SF-12 or SF-36 and
translate to improved survival.
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Appendix  

 
 
Din helse 
 
 og  
 
ditt  velbefinnende 
 
Kidney Disease and Quality of Life (KDQOL-SFTM 1.3) 
 
Dette spørreskjemaet handler om hvordan du ser på din egen helse. 
Disse opplysningene vil hjelpe oss til å få vite hvordan du har det 
og hvordan du er i stand til å utføre dine daglige gjøremål.  
 
 
 
Takk for at du svarer på disse spørsmålene! 
 
 
Kidney Disease and Quality of LifeTM Short Form (KDQOL-SFTM) 
Norwegian version 1.3 
Copyright © 1993, 1994, 1995 by RAND and University of Arizona 
 
Oversatt til norsk 2005 av Ingrid Os, overlege, professor, Nyremedisinsk avdeling, Tone Brit Hortemo 
Østhus, lege, stipendiat, Nyremedisinsk avdeling,  Toril Dammen, overlege 1. amanuensis, Psykiatrisk 
avdeling , Ullevål universitetsykehus,og Fakultetsdivisjon på  Ullevål, Universitetet i Oslo,  Inger Hilde 
Nordhus, professor, Psykologisk institutt, Universitetet i Bergen . Spørsmål 1-11  bygger på norsk 
oversettelse av  SF36 ved  Jon Håvard Loge , professor , Kompetansesenter for lindrende behandling, 
Kirugisk divisjon , Ullevål universitetssykehus og Kjell Kaasa, assisterende seksjonsleder, Prehospital 
Divisjon Aurskog/Høland ambulanse 
1. Stort sett, vil du si at din helse er: 
Utmerket 
 
 
Meget god 
 
 
God 
 
 
Nokså god 
 
 
Dårlig 
 
 
 
2. Sammenlignet med for ett år siden, hvordan vil du si at din helse stort sett er nå? 
Mye bedre nå enn for ett år siden 
 
Litt bedre nå enn for ett år siden 
 
Omtrent den samme som for ett år siden 
 
Litt dårligere enn for ett år siden 
 
Mye dårligere enn for ett år siden 
 
3. De neste spørsmålene handler om aktiviteter du kanskje utfører i løpet av en vanlig dag.  
Er din helse slik at den begrenser deg i utførelsen av disse aktivitetene nå? Hvis ja, hvor mye? 
 
 Ja, begrenser  Ja, begrenser Nei, begrenser 
AKTIVITETER meg mye meg litt meg ikke i det 
    hele tatt 
 
a. Anstrengende aktiviteter som å løpe, løfte tunge gjenstander 
delta i anstrengende idrett 
 
b. Moderat aktiviteter som å flytte et bord, støvsuge, gå en 
tur eller drive med hagearbeid 
 
c. Løfte eller bære en handlekurv 
 
d. Gå opp trappen flere etasjer 
 
 
 
e. Gå opp trappen en etasje 
 
f. Bøye deg eller sitte på huk  
 
 
g. Gå mer enn to kilometer 
 
h. Gå noen hundre meter 
 
 
i. Gå hundre meter 
 
 
j. Vaske eller kle på deg 
4. I løpet av de siste 4 ukene, har du hatt noen av følgende symptomer i ditt arbeid eller i 
andre av dine daglige gjøremål på grunn av din fysiske helse?
 
 Ja  Nei 
a. Du har måttet redusere tiden du har brukt på arbeid eller andre gjøremål 
b. Du har utrettet mindre enn du har hadde ønsket 
c. Du har vært hindret i å utføre visse typer arbeid eller gjøremål 
d. Du har hatt problemer med å gjennomføre arbeid eller andre gjøremål 
(f.eks. fordi det krevde ekstraanstrengelser) 
 
 
 
 
5. I løpet av de siste 4 ukene, har du hatt noen av følgende problemer i ditt arbeid eller i andre 
av dine daglige gjøremål på grunn av din følelsesmessige problmer (som f.eks å være 
deprimert eller engstelig)? 
 
 Ja  Nei 
a. Du har måttet redusere tiden du har brukt på arbeid eller andre gjøremål 
b. Du har utrettet mindre enn du har hadde ønsket 
c. Du har utført arbeid eller andre gjøremål mindre grundig enn vanlig 
 
 
6. I løpet av de siste 4 ukene, i hvilken grad har din fysiske helse eller 
følelsesmessige problemer hatt innvirkning på din vanlige sosiale omgang med 
familie, venner, naboer eller foreninger? 
 
 Ikke i det hele tatt Litt En del Mye Svært mye 
 
 
7. Hvor sterke kroppslige smerter har du hatt i løpet av de siste 4 ukene? 
 
 Ingen Meget svake Svake Moderate Sterke Megest sterke 
 
 
8. I løpet av de siste 4 ukene, hvor mye har smerte påvirket ditt daglige arbeid (gjelder både 
arbeid utenfor hjemmet og husarbeid)? 
 
 
 Ikke i det hele tatt Litt En del Mye Svært mye 
9.De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt det de 
siste fire ukene. For hvert spørsmål vennligst velg det svaralternativ som best beskriver 
hvordan du har hatt det. Hvor ofte i løpet av de siste fire ukene har du:.  
 
 Hele Neste hele Mye av En del av Litt av Ikke i det 
 tiden tiden tiden tiden tiden hele tatt 
     
 
a. følt deg full av tiltakslyst 
 
b. følt deg veldig nervøs 
 
c. Vært så langt nede at ingenting 
 kunne muntre deg opp  
 
d. Følt deg rolig og harmonisk 
 
 
 
e. Hatt mye overskudd 
 
f. Følt deg nedfor og trist  
 
 
g. Følt deg sliten 
 
h. Følt deg glad 
 
 
i. Følt deg trett 
 
 
 
 
10. I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske helse eller følelsesmessige 
problemer påvirket din sosiale omgang (som å besøke venner, slektninger osv.)? 
 
 
 
 Hele  Nesten En del av Litt av Ikke i det 
 tiden hele tiden tiden tiden hele tatt 
 
 
  
11. Hvor RIKTIG eller GALT er hver av de følgende påstandene for deg? 
 
  Helt Delvis Vet  Delvis Helt 
  riktig riktig ikke galt galt 
     
 
a. Det virker som jeg blir syk litt lettere 
enn andre 
 
b. Jeg er like frisk som de fleste jeg kjenner 
 
c.Jeg tror at helsen min vil forverres  
 
d. Jeg har utmerket helse 
 
 
 
 
Din nyresykdom 
 
 
 
 
 
12. Hvor RIKTIG eller GALT er hver av de følgende påstandene for deg? 
 
  Helt Delvis Vet  Delvis Helt 
  riktig riktig ikke galt galt 
     
 
a. Min nyresykdom 
forstyrrer for mye 
i  livet mitt 
 
b. Jeg bruker for  
mye av tiden min  
på nyresykdommen min 
 
 
c. Det er frustrerende  
å beskjeftige seg  
med nyresykdommen min 
  
 
d. Jeg føler meg som  
en belastning for  
min familie 
 
 
 
 
 
13. Disse spørsmålene handler om hvordan du har hatt det i løpet av de siste 4 uker. Hvert 
spørsmål besvares ved å krysse av for det alternativet   som best beskriver hvordan du har 
hatt det. 
( Sett ett kryss på hver linje) 
 
 
 Ikke i det   Litt av En del av Mye av Nesten hele Hele
 hele tatt   tiden tiden tiden tiden tiden 
     
 
a. Har du isolert deg fra  
mennesker  omkring  deg 
 
b. Har du reagert langsomt på ting, 
som har blitt sagt eller gjort 
 
c. Har du vært irritert på de  
 som har vært rundt deg?  
 
d. Har du hatt vanskelig for å  
konsentrere deg eller for å tenke? 
 
 
 
e. Har du kommet bra overens  
med andre mennesker? 
 
f. Har du vært forvirret? 
 
 
 
 
 
 
 
 
 
14. I løpet av de siste 4 uker, hvor  mye har du vært plaget av følgende 
 (Sett   i    én boks på hver linje) 
 
 Ikke plaget    veldig mye 
 i det hele tatt Litt plaget noe plaget mye plaget plaget 
  
 
a Ømme 
muskler……………….1……….……2……………3………..…….4…….………5 
 
b Brystsmerter………...1……………..2……………3……………..4……………..5 
 
c Kramper…………..…1…………….2…………….3……………..4……………..5 
 
d Hudkløe…… …….…1…………….2…………….3……………..4……………..5 
 
e Tørr hud……….……1…………….2…………….3…………….4……………..5 
 
f Kortpustethet……… 1…………….2…………….3……………..4…………….5 
 
g Svimmelhet eller 
nesten besvimelse. .….1…………….2……………3….…………..4……………..5 
 
h Mangel på 
appetitt…….………....1…………….2……………3…….………..4……………..5 
 
i Utkjørt eller   
utbrendt ……………..1…………….2…………….3……………..4…………….5 
 
j Nummenhet i hender  
eller føtter..….…….…1…………….2……………3….…………..4……………..5 
 
k Kvalme eller 
brekninger…….……..1…………….2……………3…….………..4……………..5 
 
(Besvares kun av hemodialyse pasienter) 
l Problemer med  
dialyseadgangen ? 
(fistel,kateter,graft)…..1…………….2…………….3…………….4……………..5 
 
(Besvares kun av peritoneal dialyse pasienter) 
m Problemer med  
kateterinngangen ?…….. 1…………….2…………….3……………..4…………….5 
Din nyresykdoms påvirkning på ditt daglige liv 
 
 
15. Noen personer er plaget av nyresykdommen i det daglige liv, mens andre ikke 
er det. Hvor mye plaget er du av din nyresykdom innen hvert av de følgende 
områder? 
 (Sett   i    én boks på hver linje) 
 
 
 Ikke plaget    veldig mye 
 i det hele tatt Litt plaget noe plaget mye plaget plaget 
  
 
a Begrensinger 
på hvor mye 
du kan drikke……………….1……….……2……………3………..…….4…….………5 
 
 
b Kostrestriksjon……...…….1……………..2……………3……………..4……………..5 
 
 
c Din evne til  
å klare arbeid 
i huset………………………1…………….2…………….3……………..4……………..5 
 
 
d Din evne til 
å reise………………………1…………….2…………….3……………..4……………..5 
 
 
e Din avhengighet 
av leger og annet 
helsepersonell………………1…………….2…………….3…………….4……………..5 
 
 
f Stress og bekymring 
forårsaket av din 
nyresykdom………………...1…………….2…………….3……………..4…………….5 
 
 
g Ditt seksualliv….…………1…………….2……………3….…………..4……………..5 
 
 
h Ditt utseende…….………..1…………….2……………3…….………..4……………..5 
 
 
De neste tre spørsmål er personlige og handler om din seksuelle aktivitet, men dine 
svar er viktige for å forstå hvordan nyresykdom påvirker menneskers liv. 
  
 
16. Har du hatt noen form for seksuell aktivitet de siste 4 uker? 
 (sett en ring om ett tall) 
 
 Nei…………… 1  
 Ja…………….. 2 
 
 
 Hvor stort problem var følgende for deg i løpet av de siste 4 uker? 
 (Sett       i én boks på hver linje) 
 
 
 Ikke et lite et moderat et stort et alvorlig 
 problematisk problem  problem problem problem 
  
 
 
 
a Å nyte sex ..……………….1……….……2……………3………..…….4…….………5 
 
 
b Å bli seksuelt 
opphisset……………...…….1……………..2……………3……………..4……………..5 
Gå til spørsmål 17. 
 
 
17. For å svare på det neste spørsmålet skal du bruke en skala fra 0 som betyr 
”svært dårlig” til 10 som er ”svært bra” 
 Hvis du anser at din søvn er midt i mellom svært dårlig og svært bra, setter du et 
kryss ved nummer 5. Om du anser at søvnen er et trinn bedre enn 5, markerer du 
under 6. Om du anser at søvnen din er dårligere enn 5, markerer du under ruten 4 og 
så videre. 
  
 
 
 På en skala fra 0-10 hvordan vil du i det store og hele bedømme din søvn? 
 (Sett       under ett tall) 
 
 
 Meget dårlig    Meget god 
  
  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
 
 
  
18. Hvor ofte de siste 4 uker har du… 
 (Sett   i    én boks på hver linje) 
 
 
 ikke i det litt en del mye av nesten hele hele 
 hele tatt av tiden av tiden tiden tiden tiden 
  
 
a Våknet om natten 
og hatt problemer 
med å sovne igjen………..….1…..……2…………3…...…….4……..……5……………6 
 
b Fått den mengde 
søvn som du trenger……..….1…….…..2…………3……..….4…………..5……………6 
 
c Hatt problemer  
med å holde deg 
våken om dagen…………..…1…..…….2………….3………..4…………..5…………..6 
 
 
 
 
 
19. Vedrørende din familie og venner, hvor fornøyd er du med … 
(Sett       i én boks på hver linje) 
 
 
  svært litt litt svært 
 misfornøyd misfornøyd tilfreds tilfreds  
  
 
a  Den mengde tid som 
du kan være sammen 
med din familie og 
venner……….…….….……..1………….……….2…………...………3……….………..4 
 
 
b  Den støtte du  
får fra din familie 
og venner.…….……………..1………….……….2…………...………3……….………..4 
 
 
 
 
 
20. I løpet av de siste uker, har du hatt lønnet arbeid? 
  
 
  Ja  Nei 
 
 
   1  2 
 
 
 
 
 
21. Har din helsetilstand hindret deg i å utføre lønnet arbeid? 
  
 
  Ja  Nei 
 
 
   1  2 
 
 
 
 
22. Totalt sett – hvordan vurderer du helsen din? 
 (Sett       under ett tall) 
 
 
 verst mulig   
 (like dårlig som som 
 eller dårligere enn  halveis mellom verst mulig 
 være død) og best mulig best mulig 
  
  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
Tilfredshet med din behandling/omsorg 
 
 
23. Tenk på den omsorg du mottar i forbindelse med dialysebehandling. Hvor 
tilfredsstillende vurderer du den vennlighet og den interesse som vises for din 
person? 
 (Sett ett        ) 
 
 
 svært    svært 
 dårlig dårlig noenlunde god god utmerket den beste 
 
  
 
……….1…….……2…….……3………..…….4….………5……………..6…………….7 
 
 
 
 
24. Velg det svaret som beskriver best hvordan hver og ett av de følgende 
påstandene er riktig eller galt for deg. 
 (Sett       i én boks på hver linje)  
  
 
 
 helt stort sett  stort sett helt 
 riktig riktig  vet ikke feil feil 
  
 
a  Dialysepersonalet 
oppmuntrer meg til 
å være så selvstendig 
som mulig ..……… ……..….1……….……2……………3… ……..…….4…….………5 
  
 
b Dialysepersonalet 
støtter meg i å orke 
å mestre min  
nyresykdom…………...…….1……………..2……………3……………..4……………..5 
 
Bakgrunnsinformasjon 
 
 
25. Tar du i øyeblikket noen reseptbelagte medisiner regelmessig (4 eller flere dager 
i uken) som er forordnet av legen for medisinsk behandling? Ikke ta med 
håndkjøpsmedisin som syrenøytraliserende medisiner eller hodepinetabletter 
  
 
 
  Ja  Nei 
 
 
   1  2 
 
  (hvis nei, gå videre til spørsmål 26) 
   
 
 
 
 
 
25a. Hvor mange ulike reseptbelagte medisiner tar du nå? 
 
 Antall medisiner: _________   
  
 
 
 
26. Hvor mage dager sammenlagt i løpet av de siste 6 måneder har du vært innlagt 
på sykehus (altså hvor du har overnattet på sykehus)? 
 Hvis svaret er ingen, skriv 0 
 
 Antall dager: _________ 
  
 
27. Hvor mange dager til sammen i løpet av de siste 6 mnd har du vært på 
sykehuset til behandling, men kommet hjem samme dag? 
 Hvis svaret er ingen, skriv 0 
  
 
 Antall dager: ___________ 
   
   
 
 
 
 
 
28. Hva forårsaket din nyresykdom? 
 
 Sett ring rundt ett eller flere tall 
 
 Vet ikke…………………………………………… 1 
 Høyt blodtrykk…………………………………… 2 
 Diabetes…………………………………………... 3 
 Cystenyresykdom………………………………… 4 
 Kronisk glomerulonefritt (nyrebetennelse)…… 5 
 Kronisk pyelonefritt (urinveisinfeksjoner)……. 6 
  
 Annet spesifiser____________________________ 7 
 
 
29. Når er du født? 
  
 
 År/mnd/dag: __________/______/______ 
   
 
 
 
30. Hva er den høyeste avsluttete utdannelsen du har? 
 (Sett ring rundt ett tall) 
 
 Grunnskole eller ingen utdanning i det hele tatt………….…….1 
       Ungdomskole / realskole……………………………………….…2  
 Gymnas / yrkesskole ……………………………………………...3 
 Universitet / høyskole utdanning…………………………………4 
  
 
 
 
31. Har du i løpet av de siste 30 dager… 
 (Sett ring rundt et tall) 
 
 Arbeidet heltid…………………………………………………… 1 
 Arbeidet deltid………………………………………………….... 2 
 Vært arbeidsløs, permittert eller arbeidsøkende……………… 3 
 Mottatt alderspensjon…………………………………………… 4 
 Mottatt uførepensjon……………………………………………. 5 
 Studert…………………………………………………………… 6 
 Vært hjemmeværende………………………………………….. 7 
 Ingen av de ovennevnte………………………………………… 8 
 
 
32. Hva er din husholdnings totale inntekt (alle kilder) før skatt det siste 
kalenderåret inkludert deg selv, din ektefelle eller partner, og andre som du ser 
som familie, som er en del av din husholdning (svarene dine er konfidensielle)? 
 (Sett ring rundt et tall) 
  
 
 Mindre enn 50 000 NOK……………………............................... 1 
 50 001 – 100 000 NOK…………………………...……………… 2 
 100 001 – 200 000 NOK…..……………………………….......... 3 
 200 001 – 400 000 NOK………………………………………… 4 
 400 001 – 750 000 NOK………………………………………… 5 
 Mer enn 750 000 NOK………………………………………….. 6 
 Vet ikke………………………………………………………….. 7 
  
 
 
 
33. Har noen hjulpet deg med å fylle ut dette spørsmålsskjemaet? 
 (Sett ring rundt et tall) 
 
 Ja, en lege eller annet helsepersonell…………………………… 1 
 Ja, et familiemedlem eller en venn…………………………….... 2 
 Ja, noen annen…………………………………………………… 3 
 Nei………………………………………………………………… 4 
  
 
 
Vennligst skriv dagens dato: _____________________________ 
 
 
 
        Takk for at du deltok i undersøkelsen! 





